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ABSTRACT
Eosinophilic esophagitis (EoE) is an inflammatory disease characterized by 
infiltration of eosinophils into the esophageal wall. Current diagnosis requires analysis 
of small biopsy samples, leading to possible misdiagnosis if the tissue is sampled 
insufficiently. Here we develop a minimally invasive imaging method for the detection 
and mapping of eosinophil degranulation in EoE. The idea is to have patients swallow a 
radiolabeled contrast agent specific to eosinophil granule proteins and image the full 
length of the esophagus with single-photon emission computer tomography 
(SPECT/CT) imaging.
First, we studied the patchiness of the disease by mapping an esophagectomy 
sample from a known EoE patient and found a significant variation in eosinophil 
distribution. Second, we determined and quantified eosinophil degranulation by electron 
microscopy from 9 randomly selected EoE patients and showed that the majority of 
eosinophils were associated with the release of intact granules into the epithelium. 
Third, we developed a radiolabeled contrast agent specific to eosinophil granule 
proteins. We synthesized Technetium-99m labeled heparin (99mTc-heparin) and studied 
the binding of the radiolabeled heparin to ex vivo biopsy tissues from patients. To 
evaluate the organ distribution, the dose assessment of orally administered 99mTc- 
heparin was studied in healthy mice. These findings suggest that 99mTc-heparin can be 
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Eosinophilic esophagitis (EoE) is an inflammatory disease affecting over
300,000 patients per year that is caused by the infiltration of eosinophils into the 
esophagus. EoE has become increasingly prominent over the past two decades [1-6]. 
This disease, which commonly affects children, adolescents, and young adults as well 
as senior citizens, presents with difficulty or painful swallowing (dysphagia), food 
impaction, heartburn, and chest burn [7-9]. Esophagogastroduodenoscopy (EGD) is 
performed, in which a small probe with a camera at its distal end passes into the 
esophagus, stomach, and small intestine to visualize the tissue surface of the 
gastrointestinal organs. EoE also affects the esophageal wall caliber and phenotypic 
appearance of the esophagus, such as rings or furrows, which can further develop into 
strictures that close off the esophagus, resulting in dysphagia, food impaction, and 
emergency hospital visits [10-12].
The criteria for diagnosing EoE in a biopsy specimen is the presence of 
eosinophils. Normal esophageal tissue does not contain eosinophils. The diagnosis of 
eosinophilic esophagitis is made by obtaining a medical history evaluating for 
dysphagia and performing EGD to obtain esophageal biopsies. EGD remains invasive 
and requires anesthesia with pharmaceutical agents that induce conscious sedation. The
disease affects the esophagus in a spotty manner, such that at least 5, and preferably a 
greater number of, biopsies should be obtained. Biopsies are examined by a pathologist, 
and inflammation associated with 15 or greater eosinophils per high power field (hpf, 
microscopic view equal to 0.23 mm2) satisfies diagnostic guidelines [6, 13]. Figure 1.1 
shows the hematoxylin and eosin stain (H&E stain, a typical staining method in 
histology) of a patient diagnosed with EoE versus a normal patient (absence of 
eosinophils). When clinical suspicion for EoE is high, consensus practice requires 
sampling at 4-5 sites throughout the esophagus [14-16]. However, five 2 mm by 2 mm 
biopsies represent less than 0.7% of the 20-25 cm long esophageal mucosa and may 
result in underdiagnosis of EoE if mucosal eosinophilia is particularly patchy [16].
Several studies showed that food allergies are the main culprit of EoE. EoE 
symptoms can be resolved and the inflammation in the esophagus eventually heals 
when these allergenic foods are removed from the patient’s diet [17]. A variety of 
allergy tests including blood test for IgE-mediated allergies and skin tests are used to 
identify underlying food allergies that are associated with EoE [18]. A six food 
elimination diet, which involves removing the six most common foods, that is milk, 
egg, soy, wheat, nuts, and fish, is the most common allergy diet used to treat EoE [19]. 
Also, a common drug therapy to treat EoE is budesonide, a glucocorticoid (i.e., a 
steroid).
A distinctive characteristic of eosinophils is their granules, which comprise 
markedly cationic proteins, each of which is composed of a core and a matrix. The core 
consists primarily of major basic protein 1 (MBP-1); the matrix consists of eosinophil 
peroxidase (EPO), eosinophil cationic protein (ECP), and eosinophil derived neurotoxin
2
3(EDN) [20-24]. MBP-1 is a highly basic protein with the molecular weight of 
approximately 14 kDa and isoelectric point approaching 12 [25, 26]. It is a member of 
the C-type lectin family (lectins bind sugars) and has the highest concentration in the 
eosinophil granule on a per molecule basis. EPO has the highest concentration in the 
granule per mass basis [27].
At the molecular level, eosinophils degranulate, releasing intact granules and 
individual granule proteins into both epithelial and submucosal layers. Evidence of 
eosinophil degranulation includes expression of membrane markers (such as eotaxin-3, 
IL-5), formation of vesicles, and changes in the eosinophil granule matrix. In EoE, 
eosinophil granule proteins including major basic protein (MBP-1), eosinophil derived 
neurotoxin (EDN) (an RNase2), eosinophil peroxidase (EPO), and eosinophil cationic 
protein (ECP) (an RNase3) are localized on esophageal epithelial cells [24, 28]. 
Remarkably, EDN is extensively deposited on the diseased esophagus implying 
eosinophil activation and release of EDN from its storage site in the granule matrix. 
Extracellular deposition of MBP-1 is observed during eosinophil degranulation (see 
Figure 1.2). These eosinophilic granule proteins act as inflammatory mediators and 
may cause tissue damage.
Secretion of eosinophil granule proteins occurs by eosinophil cytolysis and 
release of intact granules or by piecemeal degranulation (PMD), a unique secretory 
process characterized by transport of vesicles to the cell surface [21, 29]. Large 
vesiculotubular carriers, referred to as sombrero vesicles, because of their resemblance 
to the well-known Mexican hat, have been identified as playing a key role for moving 
eosinophil proteins from granules to the plasma membrane for extracellular release [29].
4During secretion, the eosinophil sombrero vesicles are actively formed. Figure 1.3a 
shows a typical normal eosinophil with intact individual granule proteins (dark core and 
light matrix) with an intact cellular membrane. As eosinophils degranulate, they release 
their granule protein, from both the core and matrix, into the tissue and piecemeal 
degranulation occurs as judged by reversal of staining (see Figure 1.3b).
Currently, as symptoms are unable to predict the severity of eosinophilic 
involvement, the only way to adequately monitor the severity of the disease is through 
EGD and obtaining biopsy samples, which is invasive. Patients may often need to have 
several upper endoscopies per year for food re-introduction and therapeutic evaluations 
[30]. Some patients may become noncompliant because of the cost and discomfort due 
to the method of monitoring. Additionally, there is a lack of sensitivity of biopsies in 
detecting and understanding such a patchy disease because histologically biopsy 
samples only characterize a small portion of the entire esophagus [16].
Despite the rapidly growing incidence of EoE, state-of-the-art diagnostic 
techniques remain inadequate to fully characterize this disease. As such, there is a need 
to develop a precise and comprehensive technique to image and map the distribution of 
eosinophils and deposition of eosinophil granule proteins. Such techniques will provide 
a tool to diagnose EoE and detect the eosinophil’s associated inflammation, track 
disease activity in response to various treatment regimens, and obtain previously 
unreachable insight into disease pathophysiology.
The overall objective of this research study is to develop a minimally invasive 
technique to diagnose EoE and detect eosinophil-associated inflammation. The 
infiltration of eosinophils and deposition of the eosinophil’s cationic proteins into the
5esophageal wall often leads to esophageal inflammation in EoE patients (including 
increase in pain, loss of function, and swelling of esophagus, which are classic signs of 
acute inflammation). In addition to release of eosinophil-associated products, other 
markers of inflammation include the changes in extracellular spaces, and phenotypic 
features of esophageal tissue. By eosinophil-associated inflammation, here we refer 
specifically to distinct eosinophils markers such as major basic protein, leading to 
possibility of inflammatory processes in diseased esophagi. Therefore, in this 
dissertation, we mainly focused on minimally invasive detection of the eosinophil’s 
granule protein degranulation, as part of the eosinophil’s associated inflammation.
Current diagnostic methods are invasive, costly, and limited by the number of 
biopsies, leading to possible underdiagnosis of the disease. In this research study, with 
the help of radiology imaging techniques, such as single-photon emission computed 
tomography (SPECT), we hypothesize that eosinophil-rich tissue can be distinguished 
from eosinophil-free tissue using 99mTc-heparin. To enable our goal, we will synthesize 
the radiolabeled conjugate, test the binding on human biopsy tissue, and determine 
radiological safety in animals. If successful, we can monitor the severity of 
degranulation in diseased esophagi by having the patient swallow a radiolabeled 
conjugate specific to eosinophil’s granule proteins. This project takes advantage of this 
possibility by developing a novel way to image EoE on a molecular level, which could 
potentially provide less invasive diagnostic tools to gain insight into the disease’s 
inflammation.
6Figure 1.1. Light microscopy images after H&E staining. (a) EoE tissue (presence of 
numerous eosinophils greater than 15 per hpf in peak areas). (b) Normal tissue (no 
evidence of eosinophils) [16].
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Figure 1.2. Fluorescently stained (a) EoE tissue and (b) control using antibodies to 
MBP-1 indicating that this granule protein is released in the disease state. Images 
courtesy of Dr. Kirstin Leiferman, Immunodermatology Lab at the University of Utah 
Hospital.
8Figure 1.3. Electron microscopy image of (a) Normal eosinophil with intact membrane 
and intact granule proteins. (b) Degranulating eosinophil with release of granule protein 
into the cytoplasm as seen as by the reversal of staining (light core and dark matrix; see 
Chapter 3 for further details).
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CHAPTER 2
PATCHY EOSINOPHIL DISTRIBUTIONS IN AN EOSINOPHILIC 
ESOPHAGITIS ESOPHAGECTOMY SPECIMEN:
IMPLICATIONS FOR ENDOSCOPIC BIOPSY1
2.1 Abstract
The eosinophil infiltration in eosinophilic esophagitis (EoE) is known to be 
patchy, but detailed spatial knowledge of eosinophil distributions within the esophageal 
lumen and their implications for accurate diagnosis remain unclear. We analyzed full 
circumferential cross-sections of a several centimeter long esophagectomy specimen 
from a known EoE patient and mapped eosinophil density in the lumenal epithelium. 
We applied a statistical (Monte Carlo) model to predict the minimum number of 
biopsies that would be required to make a diagnosis of EoE in areas with low, 
intermediate, and high eosinophil density in this patient. Eosinophil density shows a 
nonuniform distribution in the lumenal epithelium. Within a given cross-section, 1 to 14 
Gaussian regions or patches contained an eosinophil density above the diagnostic 
threshold for EoE (>15eos/hpf), typically between lumenal folds. Overall, 31.5% of the 
total lumenal epithelium contains eosinophil counts above the threshold for disease.
1 The material provided in this chapter is available at: J. Allergy Clin. Immunol. 2012; 
130:798-800. Reprinted and adapted with permission from Elsevier.
This data set indicates an average probability of detecting EoE as low as 62% in at least 
one out of 4-5 biopsies. Our analysis suggests that the standard protocol of 4-5 biopsies 
may result in underdiagnosis of EoE in areas of low eosinophil density. EoE patients 
would require >31, >12, or >4 random biopsies to detect the disease with 95% 
confidence from low, average, and high eosinophil density regions, respectively. The 
Gaussian distribution of eosinophil density suggests that eosinophils infiltrate from 
specific localized points in the esophagus.
2. 2 Introduction and Background 
Eosinophilic esophagitis (EoE) is characterized by patchy infiltration of the 
esophagus by eosinophils, inflammatory leukocytes which are not found in the healthy 
esophagus [1-4]. The diagnosis of EoE is established through correlation of clinical 
presentation (typically a child or young male with dysphagia or food impaction) with 
endoscopic and pathologic findings [5]. The pathologic diagnosis can be difficult since 
the degree of eosinophil infiltration varies greatly within the esophagus, leading to a 
possibility of underdiagnosis if the tissue is sampled insufficiently. When clinical 
suspicion for EoE is high, consensus practice requires sampling at 4-5 sites throughout 
the esophagus [5-8]. However, five 2 mm biopsies represent less than 0.7% of the 20-25 
cm long esophageal mucosa and may result in underdiagnosis of EoE if mucosal 
eosinophilia is particularly patchy [9]. The distribution of eosinophils in EoE is thought 
to be patchy based on small biopsy samples, but a rigorous mapping study to determine 
the characteristic size and frequency of diagnostic patches of enriched eosinophil 
density requires a large tissue specimen from an esophagectomy or autopsy. Since EoE 
patients are typically (but not exclusively) young and otherwise healthy, opportunities
13
to obtain this type of specimen are rare [10-12]. Here we report the analysis of a unique 
full circumferential esophagectomy specimen from a known EoE patient who 
underwent partial esophagectomy for a concomitant early-stage esophageal 
adenocarcinoma. We obtained serial cross-sections of the esophagus and mapped 
eosinophil density across the entire esophageal epithelium. We performed statistical 
analysis of the data with a Monte Carlo simulation to predict the number of biopsies 
required to make a diagnosis of EoE in patients with different eosinophil densities.
2.3 Methods
2.3.1 Esophagectomy. With approval from the University of Utah IRB, an 
esophagectomy specimen from a 68-year-old patient with known EoE was obtained at 
time of surgery for early-stage T1N0M0 esophageal adenocarcinoma. He presented 
with food impaction in 2008 and was found to have both nondysplastic Barrett’s 
esophagus and eosinophilic esophagitis [13]. He reported a several-year history of solid 
food dysphagia as well as seasonal allergies, but no food allergies, asthma, or eczema. 
He was treated with high-dose protein pump inhibitor (PPI) therapy. Subsequent 
biopsies performed 6 months after initial presentation demonstrated a short distal 
esophageal stricture and short-segment nondysplastic Barrett’s disease. Follow up 
biopsy in 2009 revealed invasive intramucosal adenocarcinoma in the setting of short 
segment Barrett’s esophagus. In addition, greater than 100 eosinophils (eos)/high power 
field (hpf) were seen in the surrounding benign squamous mucosa, consistent with 
persistent eosinophilic esophagitis. The patient then underwent distal esophagectomy 
without prior adjuvant or radiation treatment. After removing routine segments for
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cancer diagnosis and staging, four addition tissue segments were removed and fixed in 
formalin. The more proximal of two segments available for analysis, obtained from the 
proximal esophagus, was 2.6 cm long and 1.5 cm in diameter, and labeled by surgical 
pathology as segment 3. They reported up to 30 eos/hpf, consistent with the earlier 
diagnosis of EoE. The second esophageal segment, obtained from the distal portion of 
the esophagus beginning at the gastroesophageal junction, was 9.0 cm long and 2.0 cm 
in diameter, and was labeled as segment 2. Pathology observed eosinophilic abscesses 
and reported up to 40 intraepithelial eos/hpf in this segment. The esophagus was later 
sectioned horizontally (i.e., traverse to the esophageal longitudinal axis) at 3 mm to 5 
mm intervals to yield pairs of tissue slices separated by 3 p,m to 5 p,m (see Figure 2.1a 
for section ordering and approximate intervals). Each of the 17 sections was designated 
by surgical pathology with a number and letter representing the segment and section, 
respectively (see Table 2.1).
2.3.2 Histology, mapping, and data analysis. Each section was stained with 
hematoxylin and eosin (H&E) (see Figure 2.1b). Tissue was imaged using an Olympus 
microscope at 400x magnification. Each microscopic site or circular field of view had a 
diameter of 0.54 mm, representing 0.23 mm2 of tissue. The eosinophil count for each 
400x field was performed manually one hpf at a time all the way around the entire 
perimeter (Figure 2.1c and Table 2.1). In this study, we only counted the eosinophils in 
epithelium layer and did not map the eosinophil density in deeper tissue layers in the 
esophagus. The number of sites containing a “diagnostic” level of eosinophils [either 
15 eos/hpf (65 eos/mm2, clinically recommended criteria) or 20 eos/hpf (87 eos/mm2,
15
research purposes criteria)] was determined for each of the 17 circumferential sections 
(see Appendix A for additional information).
2.3.3 Monte Carlo simulation and statistical analysis. A Monte Carlo method 
was used to evaluate the relationship between eosinophil density and the number of 
biopsies required to make a diagnosis of eosinophilic esophagitis [14]. This simulation 
mimics the random process of selecting a biopsy site during endoscopy by using a 
random number generator to select a site from the esophagectomy map. A “biopsy” is 
defined in the simulation as four adjacent 0.54 mm fields of view, since a typical 
endoscopic esophageal biopsy specimen measures approximately 2 mm [9]. The biopsy 
was considered “positive” if at least one of the four adjacent fields of view contained at 
least 15 eosinophils. The simulation was coded in Visual Basic for Applications (VBA) 
in MS Excel 2003. The simulation was repeated two to forty times to represent multiple 
biopsies per endoscopy [5]. The average, ^, and standard deviation, o, were calculated 
over the 10,000 endoscopies simulated for each scenario considered (see Appendix B 
for additional information).
The simulations were summarized by reporting either a probability of detection 
(^) or the number of biopsies required to obtain at least one biopsy specimen meeting 
the diagnostic threshold of >15 eosinophils/hpf with a confidence level of 95% or 99%. 
The number of biopsies required was calculated for three different eosinophil densities: 
low (average of 5.7% of sites >15 eos/hpf from three lowest density sections, one from 
each of 3C, 3D, and 3E in Table 2.1), average (31.5% of sites >15 eos/hpf across all 
sections), and high (average of 79.3% of sites >15 eos/hpf from three highest density 
sections, one from 2W and both of 2U). For each eosinophil density, the 95% and 99%
16
confidence levels for EoE diagnosis (i.e., number of biopsies required to obtain a 
diagnostic tissue fragment) were determined. These were calculated by ^-1.96c and ^- 
2.58cr, respectively, from a singled tailed normal distribution.
To determine whether two consecutive biopsies will produce the same result, 
pairs of consecutively simulated biopsies were selected and classified as “positive” or 
“negative.” If both were negative, then the pair was designated as a “double miss” 
because the tissue is from a known EoE patient. If both were positive, the pair was 
designated as a “double hit.” Disparate results were classified as a “miss-hit” or “hit- 
miss.” Because the order of endoscopy remains arbitrary in the simulation, differences 
between the latter two classifications reflect numerical uncertainty.
2.4 Results
The tissue sections, summarized in Figure 2.1 and Table 2.1, show the 
eosinophil density to be highly variable in this EoE patient both axially and 
circumferentially. Figure 2.1b shows a typical 360o H&E-stained cross-section. By 
methodically counting the intraepithelial eosinophil number in each sequential 0.54 mm 
field of view, eosinophil density was mapped for the entire perimeter of each tissue 
section (Figure 2.1c and Table 2.1). The greatest peak eosinophil count was 176 
eosinophils/hpf (770 eosinophils/mm2), the average eosinophil density was 
approximately 14.8 eosinophils/hpf (64 eosinophils/mm2), and some fields of view did 
not contain any eosinophils. Figure 2.1c shows an example of eosinophil density 
variation per high power field of view (hpf on left axis) or per square millimeter (right 
axis). The histograms for all circumferential sections are provided in the Supporting
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Information. Each section contains 1 to 14 areas or patches comprised of one or more 
sites exceeding the diagnostic threshold of 15 eosinophils/hpf. These diagnostic areas or 
patches were separated by regions of lower (nondiagnostic) eosinophil density, which 
ranged from 0.5 mm to 38.3 mm in length (see Table 2.2). Correlation of eosinophil 
density in Figure 2.1c with the topology of Figure 2.1b indicates that eosinophil peak 
counts appear to cluster between lumenal folds and associate with locally increased 
vasculature.
Figure 2.1d shows a representation of eosinophil density in each tissue section, 
shaded for infiltration intensity. The greatest percentage of areas with high eosinophil 
density was seen in the distal esophagus (segment 2). In total, 31.5% of the high power 
fields contained eosinophil densities >15 eosinophils/hpf. When using the more 
stringent threshold of > 20 eosinophils/hpf, only 23.8% of high power fields were 
diagnostic (see Table 2.1).
Remarkably, Figure 2.1c shows that many of the esophageal cross-sections 
contain eosinophil infiltrates that appear to follow Gaussian distributions. The 
apparently random location of the infiltrate peaks and their Gaussian shaped 
distributions suggest that eosinophil infiltrates are triggered at specific localized points 
within the esophagus presumably by localized release of chemoattractants at “point 
sources.” (We note that, due to separation between adjacent sections, the evidence 
presented in these cross-sections cannot eliminate the possibility of line sources or 
linear foci of point sources aligned along the esophageal axis [15].)
The degree of eosinophil infiltration is shown as a function of the epithelial 
perimeter position in Figure 2.2. The total circumference of the esophageal luminal
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epithelium ranged from 24.8 mm to 63.2 mm. Within both esophagectomy segments, 
the extent of infiltration appears to generally increase with perimeter or circumference.
The spatial heterogeneity in Figure 2.1 suggests that site selection for tissue 
acquisition may be critical [6]. Current biopsy protocols recommend obtaining five 
biopsies. In addition, biopsies should be obtained from both the proximal and distal 
esophagus. To predict the optimal sampling protocol, we performed a Monte Carlo 
simulation to mimic biopsy collection practices [14]. Three distinct sampling 
procedures were simulated, namely, random sampling across the entire esophagus, at a 
particular esophageal depth, and within equal length perimeter sectors (such as 4 
quadrant locations) at one specific esophageal depth (see Figure 2.3). To take into 
consideration the differing intensities of eosinophilic infiltration in individual EoE 
patients, spatial heterogeneity in eosinophil infiltration was introduced by selecting 
random high power fields from the three lowest-density cross-sections, the three 
highest-density cross-sections, and from all 17 of the cross-sections. The lowest density 
cross-sections were taken to represent EoE patients with less robust eosinophil 
infiltrates, while the high density sampling represents EoE patients with more obvious 
disease manifestations. For each of the 9 scenarios (3 densities by 3 sampling protocols), 
10,000 endoscopies were simulated, each with 2-40 biopsies per endoscopy. The 
number of biopsies that ensures a 95% or 99% confidence interval for EoE diagnosis is 
reported in Table 2.3.
The simulations indicate that the probability of detecting EoE (>1 biopsy with 
>15eos/hpf) in a single upper endoscopy with 4-5 biopsies ranges from 62% to ~100%, 
depending on eosinophil density [6, 7]. Table 2.3 shows that sampling purely randomly
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across all sections or within equal length sectors appears to provide better detection than 
random sampling within circumferential sections (i.e., at a single esophageal depth). 
However, in all but the highest density infiltrates, sampling within equal length sectors 
would require removal of over half of the epithelium at that esophageal depth, leaving 
random sampling at multiple esophageal depths as the most feasible and informative 
sampling procedure.
Remarkably, in this specimen, a 95% confidence interval for EoE detection 
requires at least 12 biopsies for all but the highest eosinophil densities. This is in 
reasonable agreement with the conclusion of Gonsalves, et al., who examined very high 
density sections and found 4-5 biopsies per endoscopy to be sufficient. Previous work, 
however, has only considered probability of detection and not confidence of detection. 
The former represents only the mean, which may be associated with significant 
variation that only confidence interval analysis includes ( d p  regularly exceeded 0.2). 
For example, five biopsies selected purely at random return a 96.4% probability of 
detecting EoE (>15 eos/hpf in >1 biopsy), but the corresponding standard deviation is 
18.6%, leading to a confidence interval of only 59.9%. Only by increasing the number 
of biopsies to 12 does the confidence interval rise to 95% for the typical eosinophil 
densities of this patient.
We also note that in many cases, increasing the number of biopsies by only one 
or two increases the confidence interval (CI) from 95% to 99%. A 95% confidence 
interval in this context translates into one in twenty patients with a potential 
misdiagnosis. However, the increased probability of accurate detection for 5% of
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patients must be balanced against the additional risk endured by the 95% of the patient 
population for whom an extra sample provides limited insight.
Table 2.4 indicates the probability that two consecutive endoscopies with either 
5 (consensus criterion) or 8 (research criterion) biopsies will correctly diagnose the 
patient at three eosinophil densities. Five biopsies from an area of low-density 
eosinophil infiltration will yield a false negative 50.9% in at least one of the 
endoscopies in a known EoE patient. However, with more biopsies or higher eosinophil 
densities, this risk falls dramatically to 1.1-8.3%. The risk becomes negligible at high 
eosinophil density. The probability of an initial diagnosis of EoE followed by a 
misdiagnosis of EoE remission or that sampling errors will lead to an initial 
misdiagnosis of no EoE that will only be corrected with the second endoscopy are 
numerically identical as high as 20.9%, though with more biopsies or higher eosinophil 
densities, this risk can fall dramatically to 0.5-4.2% with average levels of infiltration 
and also become negligible at high eosinophil density.
2.5 Discussion
This study addresses a fundamental gap in our knowledge regarding eosinophil 
infiltration in EoE by spatially mapping the distribution of eosinophil density derived 
from a several centimeter long esophagectomy specimen from a patient with known 
eosinophilic esophagitis. The resulting distributions demonstrate significant variability 
in eosinophil density. Diagnostic areas or patches bearing >15 eosinophils/hpf are 
separated by regions with low to negligible (nondiagnostic) eosinophil density spanning
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<0.5 mm to >38 mm (see Figure 2.1c and Table 2.2). Because endoscopic biopsies 
typically sample only 2 mm of tissue, eosinophil peak infiltrates may be easily missed.
From this distinct data set, we used a statistical (Monte Carlo) simulation to 
predict the number of biopsies required for EoE diagnosis based on the underlying 
eosinophil density [14]. For the current clinical practice of 4-5 biopsies, the simulations 
indicate a 62% to ~100% probability of detecting EoE (>1 biopsy with >15 
eosinophils/hpf). This variability was not anticipated by Gonsalves, et al., who found 1 
biopsy with a criterion of >15 eos/HPF to be a 55% sensitive indicator of EoE and 
suggested that 5 biopsies are sufficient for essentially 100% EoE detection.6 At least 
part of the difference may arise from the much higher eosinophil densities observed in 
their studies (median of 107 eos/hpf where 1 hpf=0.15 mm2 versus our average of 14.8 
eos/hpf, commensurate with our high density variant). More stringent criteria for 
disease diagnosis (e.g., >20 eosinophils/hpf) increase the number of biopsies that must 
be collected.
In this patient, approximately 30% of the esophageal epithelium contained a 
“diagnostic” eosinophil density of >15 eosinophils/hpf. In order to achieve a 95% 
confidence interval for EoE detection, this patient would typically require at least 12 
biopsies at endoscopy (see Table 2.3). The extreme variability of eosinophil density in 
only this patient suggests that other patients may have equally patchy eosinophil 
distributions, and suggests that the clinical recommendations for EoE diagnosis may 
need to be reevaluated.
Our data also suggest a significant probability that a second endoscopy with 
biopsy may report resolution of pathologic esophageal eosinophilia, when in fact
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disease remains. Based on this specimen, the probability of misdiagnosis based on 
sampling error alone is as high as 20.7% at the lower eosinophil infiltration density (see 
Table 2.4), a very real possibility for some patients. This means that as many as 20.7% 
of these patients initially diagnosed with EoE would appear to have disease resolution 
upon repeat biopsy, but in reality have persistent EoE. Placebo responses (seen in up to 
9% of patients) reported in previous trials may result from inadequate sampling 
techniques alone and not actual disease resolution [16]. Others have reported that 
symptoms do not appear to correlate with disease activity, but this conclusion also 
derives from assessments of small numbers of potentially nonrepresentative biopsies 
collected blindly from within the adult esophagus [11,17]. Indeed, based on the 
perimeters or circumference for this patient, five 1 mm-3 mm biopsies represent only
0.02%- 0.71% of the esophageal lumen, and 8 biopsies represent only 0.04%-1.14% of 
the lumenal surface area of a 20 cm-25 cm adult esophagus.
We recognize that our study has limitations. Our data are derived from a single 
EoE patient and do not represent random population sampling from a broad EoE patient 
population. Additionally, this patient had esophageal adenocarcinoma, presumably 
arising from Barrett’s esophagus in the setting of gastroesophageal reflux disease 
(GERD) [18]. The presence of additional pathology injects some uncertainty into the 
data, especially in the distal esophagus (segment 2), near the site of adenocarcinoma. 
Some of the eosinophilic infiltrates could potentially be secondary to gastroesophageal 
reflux or could represent a reaction to the tumor (e.g., tumor protrusion could moderate 
food bolus migration rates allowing for extra “contact time”). However, this patient had 
known eosinophilic esophagitis for several years, was treated with high-dose protein
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pump inhibitor (PPI) therapy, and the histological features in his esophagus are strongly 
consistent with residual EoE rather than GERD or tumor reaction. In addition, we also 
studied tissue from the more proximal portion of the esophagectomy specimen, which 
was uninvolved by adenocarcinoma. Despite the potential disadvantages of using a 
specimen with other pathologic findings, this is a unique opportunity for the study of 
EoE. Prior reports of esophagectomy specimens from EoE patients are exceedingly rare, 
since the EoE population is typically young and healthy [12, 19]. Previous reports of 
esophagectomies either do not fulfill the criteria for EoE because eosinophils were only 
found in the muscularis propria and not in mucosal biopsies [19] or describe histologic 
findings only in 2 short lines [12]. To our knowledge, ours is the first and only study to 
systematically perform eosinophil counts on multiple full circumference sections of an 
EoE specimen. In addition, we have used these data in a mathematical model to predict 
the numbers of biopsies required for EoE diagnosis in tissue with varying eosinophil 
density. While our results are derived from a single EoE patient and other 
patients/phenotypes may differ in their eosinophil distributions, we believe that some of 
these results can be applied to other EoE patients. Our mathematical model calculated 
the probability of obtaining a diagnostic tissue specimen in areas of high, medium, and 
low eosinophil densities. Presumably, these findings could be extrapolated to different 
EoE patients, some of whom may present with very low or high eosinophil densities.
These spatial distributions also provide new insights that may inform studies 
into the etiology and pathogenesis of EoE. Specifically, this patient’s eosinophil 
densities appear to follow Gaussian distributions, arguing that a "point of stimulus" may 
stimulate eosinophil infiltration at specific areas within the esophagus [15]. We caution,
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however, that the centers of eosinophil infiltration cannot be determined from these 
cross-sections for much the same reason as marching along a straight line through the 
mountains does not necessarily determine the height of the tallest peak. The summit 
location must be triangulated, and there is insufficient information in these 20 sections 
alone to locate the true “peaks.” While the typical Gaussian distribution of dense 
eosinophilia spans only 1.1-2.5 mm (at base), the separation between cross-sections is 
approximately 1.6-5.4 mm. This precludes us from precisely aligning peaks within 
adjacent sections.
Finally, as esophagectomies are not routinely available in EoE, this analysis 
strongly indicates the need for improved imaging of eosinophil infiltration patterns in 
vivo to accurately diagnose and understand this disease. This suggestion is in strong 
accord with a recent challenge issued by the American Partnership for Eosinophilic 
Disorders (APFED), who called for development of more informative and less invasive 
imaging of EoE patients. This study suggests that more intensive biopsy sampling may 
lead to greater diagnostic accuracy, and provide additional insight into the disease, 
particularly in the early stages where eosinophil infiltration densities may be more 
modest but when the patient may also benefit most from measured interventions.
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Figure 2.1. Histology, mapping, and data analysis. (a) Sequential ordering of sections 
within the esophagectomy. Distances between sections are not to scale but approximate. 
Two tissues slices separated by approximately 3-5 ^m were cut for most sections. (b) 
Digital image of representative H&E stained esophageal section 3D. (c) Representative 
eosinophil density (in eos/hpf and eos/mm2) as a function of lumenal perimeter position 
in terms of microscopy sites for section 3D. (d) Eosinophil density map as a function of 
both lumenal perimeter (in cm) and axial location (not to scale) at various densities of 
<3 eosinophils/hpf or less (blue), 4-14 eosinophils/hpf (green), 15-19 eosinophils/hpf 











Figure 2.2. Number of sites with eosinophil density of >15 eosinophils/hpf versus 
length of epithelial perimeter for proximal sections 3B-3E (circles) and distal 
esophageal sections 2T-2Y (squares).
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Figure 2.3. Three sampling patterns simulated including (a) random sampling across the 
entire esophagus, (b) at a particular esophageal depth, and (c) within equal length 
perimeter sectors at one specific esophageal depth. Each panel represents the location of 
5 biopsies in the large grey dots (not to scale).
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Table 2.1. Section attributes from proximal to distal.
Section
Number
























3B 46 24.8 0.79 3 6.5% 3 6.5%
3B 48 25.9 0.83 6 12.5% 5 10.4%
3C 69 37.3 1.19 5 7.2% 3 4.3%
3C 65 35.1 1.12 4 6.2% 3 4.6%
3D 66 35.6 1.13 5 7.6% 1 1.5%
3D 64 34.6 1.10 4 6.3% 2 3.1%
3E 116 62.6 1.99 15 12.9% 8 6.9%
3E 117 63.2 2.01 6 5.1% 5 4.3%
2Y 55 29.7 0.95 13 23.6% 7 12.7%
2Y 56 30.2 0.96 17 30.4% 8 14.3%
2X 98 52.9 1.68 37 37.8% 25 25.5%
2X 95 51.3 1.63 40 42.1% 26 27.4%
2W 56 30.2 0.96 33 58.9% 24 42.9%
2W 61 32.9 1.05 38 62.3% 32 52.5%
2U 69 37.3 1.19 60 87.0% 55 79.7%
2U 68 36.7 1.17 59 86.8% 53 77.9%
2T 66 35.6 1.13 38 57.6% 29 43.9%
Totals: 1215 383 31.5% 289 23.8%
+Perimeter=# of sites x field of view (0.54 mm); equivalent diameter=perimeter/n. 
++ 15 eos/hpf=Clinical diagnostic criteria for EoE.
+++ 20 eos/hpf=Research purpose criteria.
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Table 2.2. Measured Patch Lengths.









Table 2.3. Required number of biopsies needed to obtain >1 biopsy containing >15 
eosinophils/hpf at 95% and 99% confidence intervals.







95% CI 99% CI 95% CI 99% CI 95% CI 99% CI
30 >40 36 >40 15 16
12 13 34 >40 14 15
4 5 5 6 2 2
*Simulated by randomly selecting sites from any of the 17 sections (see Fig. 3a). 
+Simulated by randomly selecting sites from within any one section (see Fig. 3b). 
§Simulated by first selecting a section, dividing the section into equal length sectors 
(e.g., quadrants for 4 biopsies) based on equal divisions of the perimeter, and then 
randomly selecting a site from within each sector (see Fig. 3c).
*
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Table 2.4. Probability that repeat endoscopy with random biopsy will detect EoE in >1 
biopsy (>15 eosinophils/hpf or 65 eosinophils/mm2) out of 5 or 8 biopsies/endoscopy.
Biopsies Miss-miss Miss-hit Hit-miss Hit-hit
Three Low Density 
Sections+ 5 9.4% 20.9% 20.7% 49.1%
All Sections 5 0.2% 3.9% 4.2% 91.8%
Three High Density 
Sections§ 5 0.0% 0.0% 0.0% ~100%
Three Low Density 
Sections+ 8 1.9% 12.5% 12.1% 73.5%
All Sections 8 0.0% 0.6% 0.5% 98.9%
Three High Density 
Sections§ 8 0.0% 0.0% 0.0% ~100%
*Percentages may not sum to 100.0% due to rounding uncertainty. 
+Representing patients with a lower infiltration of eosinophils. 
Representing patients with a large, robust eosinophil infiltrates.
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CHAPTER 3
EOSINOPHIL DEGRANULATION PATTERNS IN EOSINOPHILIC 
ESOPHAGITIS: AN ELECTRON MICROSCOPY STUDY1
3.1 Abstract
In eosinophilic esophagitis (EoE), eosinophil granulocytes accumulate and 
release granule proteins onto esophageal epithelium. However, little is understood about 
the mechanism of eosinophil degranulation in EoE. To determine and quantify 
eosinophil degranulation patterns, we studied esophageal biopsy specimens obtained at 
endoscopy from both proximal and distal esophagi of 9 randomly selected patients with 
EoE (3 female, 6 male). The specimens were fixed in glutaraldehyde, embedded in 
Epon, sectioned, and imaged by transmission electron microscopy. Eosinophils and 
their granules were identified by their distinctive morphology, and all eosinophils and 
granules were imaged. A total of 1672 images from 18 esophageal specimen blocks 
were evaluated and graded. Eosinophils were categorized based on membrane integrity 
and by cytoplasmic vesiculation as evidence of piecemeal degranulation. Granules were 
categorized based on reversal of staining (eosinophil granule core lightening) and other 
features including location within and outside of cells and membrane integrity. The
1 The material presented in this chapter has been submitted to Journal of Allergy and 
Clinical Immunology (JACI).
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results revealed that greater than 98% of eosinophils infiltrating the esophagus in EoE 
demonstrate morphological abnormalities ranging from granule changes with reversal 
of staining to marked cytoplasmic vesiculation to loss of membrane integrity with 
cytolytic disruption and release of intact, membrane-bound granules into the tissues. 
Approximately 81% of eosinophils showed membrane disruption. Extracellular 
granules were abundant in at least 70% of the images and about 50% of these granules 
showed reversal of staining. Based on the prominence of tubulovesicular development, 
piecemeal degranulation appears closely related to the other morphological changes in 
eosinophils in EoE. These findings reveal that eosinophils in EoE esophageal biopsy 
specimens are abnormal with greater than 80% showing cytolysis, and, therefore, that 
evaluation by light microscopy after hematoxylin and eosin (H&E) staining may not 
accurately reflect eosinophil numbers or involvement.
3.2 Introduction
Eosinophilic esophagitis (EoE) is an increasingly common disease characterized 
by eosinophil invasion of the esophageal mucosa, where eosinophil granulocytes (a type 
of white blood cell) accumulate and are activated. Activated eosinophils release granule 
proteins into both epithelial and sub-mucosal layers [1-4]. Evidence of eosinophil 
activation includes expression of membrane markers, formation of cytoplasmic vesicles, 
and changes in eosinophil granules with loss of electron density of the granule cores [5]. 
In EoE, eosinophil granule proteins including major basic protein 1, eosinophil derived 
neurotoxin (also known as Ribonuclease2), eosinophil peroxidase, and eosinophil 
cationic protein (also known as Ribonuclease3) are localized on esophageal epithelial
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cells [4, 6]. Remarkably, eosinophil derived neurotoxin is extensively deposited on the 
diseased esophagus implying eosinophil activation and release of eosinophil derived 
neurotoxin from its storage site in the granule matrix [4]. However, the mechanisms 
responsible for eosinophil activation and the process by which granule proteins are 
deposited in the disease-affected esophagus remain incompletely described.
Secretion of eosinophil granule proteins occurs by eosinophil cytolysis and 
release of intact granules, which then liberate granule proteins, or by 
piecemeal degranulation (“piece by piece” release of eosinophils granule contents), a 
unique secretory process characterized by transport of vesicles to the cell surface [7, 8]. 
Tubulovesicular carriers, referred to as sombrero vesicles because they resemble the 
well-known Mexican hat, have been identified as playing a key role for transporting 
eosinophil proteins from granules to the plasma membrane for extracellular release [8]. 
Therefore, loss of membrane integrity is associated with cytolysis, and the presence of 
cytoplasmic cytoplasmic vesiculation, including sombrero vesicles, is taken as evidence 
of piecemeal degranulation
Here we identified and quantified eosinophil degranulation patterns by 
transmission electron microscopy in esophageal biopsy specimens from patients with 
EoE. The patterns were classified and graded according to cell membrane integrity, 
cytoplasmic vesiculation, granule morphology with respect to core staining and granule 
membrane integrity, and the occurrence of extracellular granules.
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3.3 Materials and Methods
3.3.1 Patients. Nine patients (3 female, 6 male) were randomly selected from 20 
patients participating in a study of omalizumab treatment in EoE (IRB 0013623; A Pilot 
Study of the Treatment of Eosinophilic Esophagitis With Omalizumab, 
ClinicalTrials.gov Identifier: NCT00123630). All of these patients satisfied diagnostic 
criteria for EoE [3]. Esophageal biopsy specimens were obtained during endoscopy 
concurrently for histology and for transmission electron microscopy at baseline before 
entering the study. Maximum esophageal eosinophil counts derived from examination 
after staining formalin-fixed biopsy specimens with hematoxylin and eosin (H&E) for 
individual patients are included in Table 3.1 (referred to in Results, below). All patients 
had at least 15 eosinophils per high power field (hpf) at 400X magnification in at least 
one biopsy specimen after high dose acid suppression therapy (twice daily proton pump 
inhibitor) for 8 weeks and before commencing treatment with omalizumab (or placebo 
control).
3.3.2 Electron microscopy. Tissue specimens were fixed in 2.5% glutaraldehyde, 
postfixed in 4% osmium tetroxide, dehydrated in graded ethanol, and stained with 
uranyl acetate and Reynolds lead citrate. A total of 18 tissue blocks, one biopsy 
specimen from proximal and distal esophagus from each of the 9 patients, were 
sectioned. Thin sections (90 p,m thick) from each block were mounted on separate 
electron microscopy grids and then examined by transmission electron microscopy 
(Hitachi H7100, Gatan digital camera). For each section, the operator systematically 
scanned across the grid left to right and top to bottom at 2000 X magnification and 
photographed every eosinophil and all granules, both intracellular and extracellular,
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identified based on the distinctive morphology of the cells and granules, particularly the 
characteristic cytoplasmic granule cores. The tissue sections from the distal and 
proximal esophagus specimens from each patient were evaluated together.
3.3.3 Eosinophil classification. A total of 1672 images were acquired during the 
grid scans, and all were examined and graded. Three graders (HS, LHH, and GJG) 
individually and independently inspected each image. Averages of the three graders are 
reported. (Detailed averages and standard deviations of 1672 electron photomicrographs 
graded by three individuals are provided in Appendix C.) Eosinophils and their 
granules in the images were evaluated based on cell membrane integrity, occurrence of 
cytoplasmic vesiculation recording the specific presence of sombrero vesicles, granule 
morphology, and occurrence of extracellular granules. Eosinophils that were only 
partially captured within an image were not graded.
Figures 3.1-3.5 show a gallery of findings in the images analyzed that were 
defined and inventoried: 1. Normal eosinophil (without granule changes, no 
cytoplasmic vesiculation, and no cytoplasmic membrane disruption, Figure 3.1); 2. 
Intracellular eosinophil granules displaying reversal of staining (core relatively 
radiolucent compared to the matrix, Figure 3.2); 3. Prominent cytoplasmic vesiculation, 
including piecemeal degranulation (tubulovesicular development with sombrero 
vesicles, Figures 3.2, 3.3, and 3.4); 4. Occurrence of extracellular eosinophil granules 
(individual eosinophil granules or clusters of fewer than 5 eosinophil granules with loss 
of cell membrane and/or surrounding cytoplasm, Figure 3.5). Cytoplasmic membrane 
integrity was classified as intact (no membrane loss), mainly intact (<20% membrane 
loss), partially disrupted (>20% membrane loss), or fully disrupted (no recognizable
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membrane). Each category was tabulated only once per image, although multiple 
categories could be marked for that image. For example, if in one electron micrograph, 
10 free granules were present, 6 displaying reversal of staining and 4 without granule 
changes, each category (reversal of core staining and no granule changes) was counted 
once.
3.4 Results
We examined the ultrastructural appearance of eosinophils and their granules in 
esophageal biopsy specimens by transmission electron microscopy from 9 patients with 
EoE by examining 1672 electron microscopic images obtained from systematically 
scanning grids of tissue sections from the specimens. We observed a spectrum of 
morphologies ranging from rare intact eosinophils with appearances comparable to 
eosinophils in peripheral blood of healthy persons (Figure 3.1) [9], to many cells 
showing disruption and loss of cytoplasmic membranes (Figure 3.4), to prominent 
cytoplasmic changes (Figures 3.2 and 3.3), including cytoplasmic vesiculation, 
especially with sombrero vesicles, and granules showing reversal of core staining 
(Figure 3.2) and to individual extracellular eosinophil granules scattered in the 
intercellular spaces among esophageal epithelial cells (Figure 3.5). We scored each 
image for the presence of eosinophils and extracellular granules; 809 of the images 
showed one or more eosinophils, defined as at least 5 eosinophil granules in a cluster 
and in close proximity regardless of membrane integrity, and 1185 images showed 
extracellular granules, defined by characteristic core morphology with fewer than 5 
clustered in an area of the image. We further categorized eosinophils as to their specific
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features including whether they had intact or disrupted cell membranes, by the presence 
of cytoplasmic vesicles including sombrero vesicles, because these have been identified 
in association with eosinophil piecemeal degranulation [8], and, for the intracellular 
granules, similar to the extracellular granules, by granule core morphology, particularly 
whether the granules showed reversal of core staining.
In the 1672 electron micrographic images, 900 eosinophils were recognized; the 
overall distribution of findings in these 900 eosinophils is represented in the Venn 
diagram in Figure 3.6 including overlap when more than one finding was observed. Of 
the 900 eosinophils, 80.6% showed loss of membrane integrity, varying from <20% loss 
to total loss of cytoplasmic membrane. Of the 80.6% eosinophils with loss of membrane 
integrity, 43% had fully disrupted cytoplasmic membranes. Considering cytoplasmic 
changes within the eosinophils, we found that most of the eosinophils, 91.6%, displayed 
increased cytoplasmic vesiculation, with the presence of sombrero vesicles in greater 
than 50%; sombrero vesicles could not always be identified definitively in the 
eosinophils with vesiculation, in part, likely because the sections were thin and may not 
have included identifying features and likely because the extent of the vesiculation in 
some of the cells obfuscated the defining appearance of sombrero vesicles. Most of the 
900 eosinophils, 88%, demonstrated granule changes, especially reversal of core 
staining. Most of the eosinophils examined in the images displayed more than one of 
the categorized features; for example, as diagramed in Figure 3.6, 70.3% of the 900 
eosinophils showed loss of membrane integrity, cytoplasmic vesiculation including with 
sombrero vesicles, and reversal of granule core staining. Other overlapping features are 
detailed in the legend to Figure 3.6. Very few of the eosinophils (1.3%) appeared
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normal (not on diagram) with intact membranes and no evidence of cytoplasmic 
vesiculation or granule changes.
We observed a surprising frequency of extracellular eosinophil granules in these 
esophageal specimens. As noted above, in 1672 electron photomicrographs, 1185 
images (71%) showed eosinophil granules, recognizable by their characteristic 
morphology, clearly outside of cells (Figure 3.5). From the 1185 images of free 
granules, 48% showed abnormalities with loss of core density and/or granule membrane 
loss. In many images, a single granule was present without other eosinophil remnants. 
In other images, isolated eosinophil granules were found with remnants of cell 
structures such as nuclear fragments. Many of the free granules were in fields largely 
devoid of other structures suggesting the presence of tissue edema, likely in dilated 
intercellular spaces.
Table 3.1 summarizes information individually for each patient and presents 
observations including the maximum eosinophil counts in esophageal biopsy specimens 
by H&E histology and average percentages of common findings in the images, that is, 
extracellular eosinophil granules (71% of images, 1185 of 1672 electron 
photomicrographic images) and eosinophils showing both reversal of granule core 
staining and cytoplasmic vesiculation including sombrero vesicles (83.2%, 749 of 900 
eosinophils), and proportions of normal eosinophils. The total number of images graded 
for each patient and the total number of eosinophils (excluding the free granules ) are 
charted. Note that the data are presented in percentage of total number of images graded 
per patient for the extracellular granules and in percentage of the total number of 
eosinophils identified per patient for the combined features of cytoplasmic vesiculation
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and reversal of granule core staining and for normal eosinophils. The results show that 
the patients with the highest IgE levels (patients 3 and 7), also had high proportions of 
images with extracellular granules and normal eosinophils, although the normal 
eosinophil numbers are small. Patient 7, with an IgE level of 609 IU/mL, had the 
highest percentage of free granules (93.2%).
3.5 Discussion
The diseases in which eosinophil degranulation is prominent and the processes 
by which eosinophils release granule proteins into tissues have been studied for almost 
three decades. Identification and isolation of eosinophil granule proteins permitted 
development of antibodies to recognize the granule proteins in tissues and investigate 
their participation in disease [10]. One of the first studies was of tissues from patients 
dying of bronchial asthma. As expected, striking eosinophil infiltration was present, but 
unexpectedly, dramatic deposition of the eosinophil granule major basic protein 1 
occurred on bronchial epithelium, in mucous plugs and in respiratory epithelium [11]. 
Subsequent studies have largely confirmed the remarkable occurrence of eosinophil 
granule protein deposition in affected tissues from a wide variety of diseases [12-23]. 
Perhaps this is most striking in atopic dermatitis (an inflammatory skin disorder) in 
which intact eosinophils are not or minimally increased, but affected skin shows 
striking deposition of eosinophil granule proteins [24].
Studies of the mechanisms of eosinophil degranulation in diseased tissues show 
two key modes of granule protein release. Electron microscopic evidence demonstrates 
that, with eosinophil activation, there is loss of the usual granule core electron density
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indicating that the core protein, major basic protein 1 [25], has been released [26]. 
Electron microscopic evidence also demonstrates cytolytic changes in eosinophils and 
the accompanying presence of extracellular eosinophil granules with intact cores, often 
with reversal of granule core staining [27, 28]. In vitro studies have shown secretion of 
eosinophil granule proteins by vesicular transport and, in particular, in association with 
tubulovesicular development including sombrero vesicles [8]. Thus, two predominant 
mechanisms of eosinophil degranulation are known, cytolytic degranulation and 
piecemeal degranulation. Cytolytic degranulation is shown by disruption of the cell 
membrane and granules deposited outside of cells (typically associated with increased 
inflammatory actions of eosinophils), whereas piecemeal degranulation is associated 
with cytoplasmic vesiculation [8]. Analyses of tissues from patients with atopic 
dermatitis showed evidence of both cytolytic disruption of eosinophil membranes and 
extracellular granules [28]. A quantitative study of the mechanisms of eosinophil 
degranulation in nasal polyps found that approximately 33% of eosinophils had 
undergone cytolysis, whereas most eosinophils showed evidence of piecemeal 
degranulation [7].
In this study, we found that almost all of the eosinophils invading the esophagus 
in EoE showed changes of activation and degranulation with marked cytoplasmic 
vesiculation and varying degrees of membrane disruption. These changes were 
associated with the release of intact, membrane-bound granules into the tissues. The 
proportion of eosinophils with no or one change was remarkably small; 1.3% of 
eosinophils appeared normal without change; eosinophils with cytoplasmic vesiculation 
and no loss of membrane integrity or reversal of granule core staining comprised 1.7%;
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eosinophils with reversal of granule core staining and no loss of membrane integrity or 
cytoplasmic vesiculation comprised 2%; and eosinophils with disruption of membrane, 
no cytoplasmic vesiculation or reversal of granule core staining comprised 0.9%. 
Therefore, fewer than 6% of the eosinophils showed only one or none of the scored 
features and approximately 93% showed two or three of the features.
Figure 3.7 is a bar graph summarizing the distribution of features observed in 
the eosinophils in the biopsy specimens from the 9 patients with EoE based on the 
evidence that activated and degranulating eosinophils exhibit reversal of granule core 
staining and piecemeal degranulation. In comparison to the previous study showing the 
predominance of piecemeal degranulation over cytolysis [7], we observed that the 
majority of eosinophils, over 80%, undergoing piecemeal degranulation and reversal of 
granule core staining also showed cytolysis as evidenced by loss of cytoplasmic 
membrane integrity, 70.3% (see Figure 3.6). This finding suggests that cytoplasmic 
vesiculation leads to enhanced secretion and eosinophil cytolysis.
Another striking finding in these studies was the frequency of extracellular 
eosinophil granules in EoE tissues indicating that cytolysis results in liberation of 
granules into extracellular sites. Studies of isolated eosinophil granules have 
demonstrated that extracellular granules retain secretory activity and, thus, have the 
ability to secrete individual granule proteins into tissues after stimulation [29]. Notably, 
prior studies demonstrated that striking eosinophil granule protein deposition occurs in 
EoE [4, 6]. The compilation of findings in this electron microscopic study along with 
the existing understanding of eosinophil activity provides strong evidence of eosinophil
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activation with degranulation in EoE tissues including deposition of cytotoxic granule 
proteins.
The findings reported in this study further indicate that a large proportion of 
eosinophils in EoE biopsy specimens enumerated by light microscopy after H&E 
staining are undergoing cytolysis leading to release of granules and granule proteins 
onto esophageal tissues. The finding that approximately 80% of recognizable 
eosinophils by electron microscopy in biopsies from patients with EoE are undergoing 
cytolysis suggests that most of eosinophils counted by pathologists using light 
microscopy are, in fact, already showing membrane disruption and, thus, classifiable as 
dying cells. Along with the observations that striking eosinophil granule protein 
deposition occurs in EoE tissues, these observations provide compelling evidence that 
the full gamut of pro-inflammatory activities of the granule proteins is unleashed onto 
the epithelial cells. Moreover, it seems likely that eosinophil participation in EoE is 
only partly recognized by enumerating eosinophils. The possibility exists that, in some 
cases, the process of eosinophil cytolysis and loss of morphology is sufficiently 
advanced that few, if any, intact cells are recognizable. In these cases, one would 
overlook a diagnostic criterion for EoE when the effects of eosinophil inflammation are 
maximal. Overall, our findings imply that localization of eosinophil granule proteins, 
using immunostaining, for example for major basic protein 1 or cytochemical 
localization for eosinophil peroxidase, may be a better indicator of disease activity than 
counting of intact, and dying, eosinophils.
47
Figure 3.1. Eosinophil with normal granules, no evidence of cytoplasmic vesiculation, 
including sombrero vesicles and fully intact cytoplasmic membrane. A, B, and C show 
individual intact membrane-bound, cytoplasmic granules.
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Figure 3.2. Eosinophil with intact cytoplasmic membrane showing reversal of granule 
core staining and cytoplasmic vesiculation. A, C, and D show reversal of granule core 
staining with radiolucent core areas. B shows an intact normal-appearing granule with 
an adjacent sombrero vesicle to the right.
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Figure 3.3. Eosinophil showing partial cytoplasmic membrane disruption, granules with 
reversal of core staining, overall increased cytoplasmic vesiculation with sombrero 
vesicles. A shows an intact granule and sombrero vesicles. B shows cytoplasmic 
vesicles. C shows a cytoplasmic granule with reversal of core staining.
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Figure 3.4. Eosinophil showing fully disrupted cell membrane and cytoplasmic 
vesiculation. A, B, and C show numerous sombrero vesicles.
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Figure 3.5. Eosinophil granules in epithelial intercellular spaces.
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Figure 3.6. Venn diagram of the average percentage of findings in EoE esophageal 
eosinophils (n = 900 eosinophils) by transmission electron microscopy scored by 3 
observers based on membrane integrity, cytoplasmic vesiculation including sombrero 
vesicles, and reversal of granule core staining. As represented here, 70.3% of the 
eosinophils showed all of the three features. Considering eosinophils with two features, 
76.9% (70.3%+6.6%) showed loss of membrane integrity and cytoplasmic vesiculation 
including sombrero vesicles; 73.1% (70.3%+2.8%) showed loss of membrane integrity 
and reversal of granule core staining; and 83.2% (70.3%+12.9%) showed cytoplasmic 
vesiculation with sombrero vesicles and reversal of granule core staining. Relatively 
small proportions of the eosinophils demonstrated only one feature, 0.9% showed loss 
of membrane integrity alone, 1.7% showed cytoplasmic vesiculation with sombrero 
vesicles alone, and 2% with reversal of granule core staining alone. Only 1.5% of 
eosinophils showed cytoplasmic edema with no loss in membrane integrity and no 
evidence of cytoplasmic vesiculation or reversal of staining (not on diagram), and 1.3% 
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Figure 3.7. Percentage of eosinophils with cytoplasmic vesicles and granule 
abnormalities from electron microscopy of 9 EoE patients (PMD = piecemeal 
degranulation).
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Table 3.1. Patient’s age, gender, serum IgE level, maximum eosinophil (Eos) numbers 
by H&E histology of formalin-fixed esophageal biopsy specimens, number of electron 
micrographic images from examing esophageal biopsy specimen grids and number of 
eosinophils (excluding free granules) in the images, and average percentage of 
eosinophils showing piecemeal degranulation (PMD) and reversal of staining, and the 































1 50 / M 116 28 253 / 120 76.4 84.5 0.0
2 28 / M 82 33 263 / 188 67.4 73.2 0.2
3 29 / M 554 28 226 / 92 74.3 79.3 4.0
4 44 / F 32 27 114 / 78 62.0 91.5 0.9
5 36 / F 171 30 169 / 131 55.8 78.4 2.0
6 23 / M 53 16 129 / 68 71.8 97.0 1.5
7 36 / F 609 30 185 / 33 93.2 72.7 7.1
8 29 / M 82 30 188 / 110 65.7 92.1 0.0
9 26 / F 35 47 145 / 80 65.3 89.6 0.8
* International units per mL.
** Calculated based on number of images showing free granules/total number of images 
x 100.
*** Calculated based on number of eosinophils showing these abnormalities/total 
number of eosinophils x 100.
hpf= high power field (400X magnification).
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CHAPTER 4
99MTECHNETIUM-LABELED HEPARIN: A NEW APPROACH 
TO DETECTION OF EOSINOPHILIC ESOPHAGITIS- 
ASSOCIATED INFLAMMATION1
4.1 Abstract
Here we identify and test an innovative imaging strategy to detect inflammation 
in eosinophilic esophagitis (EoE). As eosinophils degranulate, they deposit markedly 
basic proteins including major basic protein (MBP-1) not normally present in the 
esophagus. Here we evaluate binding of a radiolabeled anionic probe to these proteins 
in diseased esophageal tissue. We exposed biopsy specimens from EoE patients to 
heparin labeled with technetium 99m (99mTc). We found significant binding of 99mTc- 
heparin to eosinophil enriched tissues using a single photon emission computed 
tomography (SPECT) instrument. These findings identify 99mTc-heparin as a potential 
probe for investigation of eosinophil driven inflammation associated with EoE.
1 The material presented in this chapter has been accepted in Journal of Allergy and 
Clinical Immunology (JACI). 2013. Epub a head of print. Reprinted and adapted with 
permission from Elsevier. !
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4.2 Introduction
In EoE, eosinophils infiltrate the esophagus, where they degranulate, releasing 
cytotoxic granule proteins, including MBP-1. However, the variability of eosinophil 
involvement presents a diagnostic challenge to the gastroenterologist as current 
diagnosis requires invasive esophagogastroduodenoscopy (EGD) with a minimum of 5 
biopsies, representing less than 0.7% of the esophageal surface. The disease is known to 
be patchy, which may result in underdiagnosis, particularly for mild to moderately 
involved patients [1, 2]. To understand this disease, improved, preferably noninvasive, 
methods to characterize the severity o f eosinophil-associated inflammation are required.
We propose a novel strategy to localize cationic eosinophil granule proteins 
using anionic heparin radiolabeled with 99mTc. Proteins deposited in the esophagus 
after eosinophil degranulation, such as MBP-1, are primary candidates, because they are 
absent in the normal esophagus. Here we hypothesize that 99mTc-heparin binds avidly to 
cationic eosinophil granule proteins, including MBP-1, and can be used to determine the 
presence of eosinophil products in the diseased esophagus using SPECT imaging [3]. 
Previous studies have shown that MBP-1 is deposited in the esophageal tissues and is 
available for binding [4, 5]. Heparin is a promising candidate because it has a very high 
negative charge density (MBP-1 has a correspondingly high density of positively 
charged moieties) and is not absorbed from the GI tract [6-8].
4.3 Materials and Methods
Solutions of stannous chloride (40 mg/mL, Sigma 243523) were prepared in 
deionized water under flowing nitrogen. A 0.5 mL aliquot was filtered and mixed with
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1.00 mL NaCl (1.00 M) plus 150 mg of preservative free heparin (10,000 IU/mL, APP 
Pharmaceuticals, NDC 63323-543-02). Approximately 100 mCi of freshly eluted 99mTc 
was added and mixed for 30 minutes at room temperature. Aliquots containing 
approximately 10 mCi of 99mTc and 20 mg of heparin were removed for tissue 
experiments. The labeling efficiency, measured by paper chromatography Whatman # 
31 with acetone, showed more than 98% binding of heparin to 99mTc. Radiolabeled 
heparin was also analyzed by Sephadex G25 column chromatography (HiTrap 5 mL 
desalting columns, GE healthcare, 17140801) with 0.15 M NaCl as the elution buffer, 
and 1.0 mL fractions were collected. Radioactivity eluted at fraction 4 (free 99mTc elutes 
at fraction 13), demonstrating that all of the 99mTc eluted at the void volume and 
confirming that there is no unbound 99mTc in the radiolabeled heparin. The stability of 
99mTc-heparin in an acidic environment was tested by diluting in artificial gastric juice 
(Carolina Biological Supply Company, Burlington, NC, 864603) and showing that its 
properties were unaltered using both paper chromatography and Sephadex G25.
Esophageal biopsies were collected from normal subjects and patients 
participating in a prior elemental diet study (IRB 00040035 University of Utah) and 
kept frozen at -70°C. Biopsies from each patient were selected for histological analysis 
for eosinophil density or radiolabeling. Biopsies from normal subjects and EoE patients 
who resolved their esophageal eosinophilia under the elemental diet (hence the 
designation “resolved”) were chosen as negative controls. Tissues from normal, 
resolved EoE, and active EoE patients were incubated with the 99mTc-heparin, washed 
in buffered saline, and imaged using SPECT.
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The activity of radiolabeled biopsy tissues was measured using a dose calibrator 
(Capintec model CRC-15R). Two-dimensional planar static images of the radiolabeled 
biopsies were obtained using the Ecam SPECT instrument (Siemens). The images were 
acquired for 3 minutes each using a 1.0 magnification, 256 by 256 matrix size. 
Correlation between eosinophil densities and SPECT counts obtained by 2D imaging 
were evaluated by Spearman rank correlation analysis. The cutoff SPECT intensity 
between active (e.g., >15 eosinophils per high power field (hpf), equivalent to >68 
eosinophils/mm ) and resolved (e.g., <15 eosinophils/hpf) EoE cases was determined by 
minimizing the difference between Gaussian fits. SPECT intensities above the cutoff 
were compared to those below using a Student t test. Data were fit with power law, 
exponential, and second order polynomial correlations. The power law fit displayed the 
highest r2 value and was used to determine the eosinophil density corresponding to each 
cutoff.
4.4 Results
Table 4.1 presents the SPECT counts of each biopsy, summarizing its 
radioactivity and eosinophil density. Histopathological analyses confirmed that only 
samples 1-5 had eosinophil levels >15 eosinophils/high power field (hpf). The images 
(Figure 4.1) suggest that active EoE cases can be differentiated from resolved EoE (EoE 
patients treated) cases using this technique. Indeed, the Spearman rank correlation 
analysis finds a monotonic correlation between eosinophil density and SPECT count 
(r=0.67; p<0.05). Remarkably, even though the eosinophil densities are derived from 
the same patient but not from the same biopsy specimen used for SPECT imaging,
nevertheless, tissues from inflamed patients displayed significant binding to 99mTc- 
heparin that correlates with eosinophil density.
Using 15 eosinophils as the threshold for inflammation suggests a cutoff in 
SPECT intensity of 39000. However, this is not a clean cut off because sample 5, which 
has an eosinophil density of 21 eosinophils/hpf, lies below the cutoff. The alternative is 
to recognize that sample 6 has 10 eosinophils, which may be associated with significant 
MBP-1 release. Grouping samples 1-6 as inflamed and samples 7-8 as uninflamed finds 
a cutoff in SPECT intensity of 22400. The corresponding eosinophil density obtained 
via a power law fit is 2.6 eosinophils/hpf, indicating the sensitivity of this assay for 
eosinophil granule products.
4.5 Discussion
These proof-of-principle experiments clearly demonstrate that, first, heparin can 
be labeled with 99mTc in the presence of fresh stannous chloride without any chelating 
agent. Second, eosinophil density correlates with 99mTc emission as measured both in a 
well counter and by SPECT. Third, eosinophil enriched tissues can be distinguished 
from eosinophil poor tissues using 99mTc-heparin conjugate and SPECT quantitation 
(The correlation between the activity and SPECT intensity is further demonstrated in 
Appendix D). Yet, the analysis finds that 15 eosinophils/hpf may not be the best cutoff 
to distinguish granule protein deposition. For example, our analysis finds significant 
SPECT counts at 10 eosinophils/hpf (see sample 6 in Table 4.1). Some variation around 
the nominal cutoff of 15 eosinophils/hpf is not unexpected because eosinophil 
presentation in EoE is known to be patchy, the eosinophil density and SPECT count are
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not from identical biopsies but from the same patient, and some eosinophils may have 
degranulated completely leaving only the MBP-1 signature [2]. While the full set of all 
proteins that bind 99mTc-heparin remains unclear, we assume they are likely derived 
from eosinophils because of the cationicity of the eosinophil granule proteins and their 
known abilities to bind heparin. Other products derived from mast cells, such as mast 
cell tryptase, may also bind 99mTc-heparin because tryptase is known to bind to heparin 
[9,10]. However, prior studies discourage belief that tryptase deposition is wide spread 
[11].
This is the first and only study to experimentally evaluate radiolabeled contrast 
agents for detection of EoE-associated inflammation. Further studies are underway to 
rigorously validate this technique as an assay for eosinophil involvement and to 
evaluate oral administration of 99mTc-heparin in the presence of a mucosal layer and 
esophageal peristalsis. Although radioactivity offers considerable sensitivity as 
demonstrated, the binding of the heparin conjugate to the eosinophil’s granule proteins 
will likely depend on the esophageal residence time (or passage rate), which will have 
an impact on the sensitivity of the assay. However, we believe that the current findings 
are important because they provide a new avenue for quantification of inflammation. If 
successful, this strategy will provide unprecedented insight into the specific 
involvement of eosinophils and their granule proteins within the esophagus of EoE 
patients, which will create improved opportunities to understand the disease 
pathogenesis and treatment efficacy.
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Figure 4.1. Experimental results. (a) 2D planar SPECT image of biopsies from normal, 
active EoE, and resolved EoE patients. From right the samples are from patient number:
5, 3, 7, 6, 4, 2, 8, 1, 9, and 10 in Table 4.1, respectively. Multiple SPECT images 
collected on multiple days were spliced together to make panel a (the four samples on 
the right, the four in the middle, and the two on the right were taken on different days). 
(b) SPECT count of biopsies as a function of eosinophil loads from the same patient.
65
Table 4.1. Radioactivity measurements, histological data, and the SPECT count of EoE 












1 Active EoE 78 122.5 59634
2 Active EoE 51 87.1 40474
3 Active EoE 53 75.7 46457
4 Active EoE 46 98.1 59923
5 Active EoE 78 52.4 31780
6 Resolved EoE 10 100 47048
7 Resolved EoE 0 19.9 13202
8 Resolved EoE 0 27.7 17518
9 Normal 0 21.4 17740
10 Normal 0 41.3 25766
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CHAPTER 5
BIODISTRIBUTION AND DOSE ASSESSMENT OF ORALLY 
ADMINISTERED 99MTC-HEPARIN IN MICE: A CONTRAST 
AGENT FOR EOSINOPHILIC ESOPHAGITIS 
ASSOCIATED INFLAMMATION1
5.1 Abstract
99mTc-heparin is a targeted contrast agent to identify localized inflammation in 
eosinophilic esophagitis (EoE), because the markedly basic eosinophil granule proteins, 
such as major basic protein 1 (MBP-1), that are deposited in inflamed regions of the 
esophagus and other gastrointestinal (GI) organs bind strongly to heparin. Here we 
evaluate the distribution of 99mTc-heparin administered orally to mice (C57-BL/6). 
99mTc-heparin (0.5 mCi/mouse, 1.5 mg) was administered by oral gavage. Organ 
specific distributions and dosimetry were evaluated at 0.75, 1.5, 3, 6, 18, and 30 hours 
after administration. The results show that 99mTc-heparin is not absorbed significantly 
through the gastrointestinal (GI) tract into other bodily tissues. The highest observed 
activity occurred mainly in stomach, small intestine, and colon. These findings suggest
1 The materials provided in this chapter have been submitted to Journal of Nuclear 
Medicine and Biology.
that 99mTc-heparin will be well tolerated in patients and initiate a new avenue for 
clinical detection of eosinophil-associated inflammation in the GI tract.
5.2 Introduction
Eosinophilic esophagitis (EoE) is an inflammatory disease characterized by 
infiltration of eosinophils into the esophagus and has become increasingly prominent 
over the past two decades [1-4]. This disease, which commonly affects children, 
adolescents, and young adults, induces difficult or painful swallowing (dysphagia) and 
food impaction necessitating emergency intervention [5,6]. In such cases, 
esophagogastroduodenoscopy (EGD) must be performed, in which a fiber optic tube is 
inserted into the upper gastrointestinal tract, to remove the obstruction.
The diagnosis of EoE is made by obtaining a medical history of dysphagia and 
performing EGD to obtain esophageal biopsies. The disease affects the esophagus in a 
spotty manner, such that 5 or preferably more biopsies should be obtained [6]. Biopsies 
are examined by a pathologist, and inflammation associated with 15 or greater 
eosinophils per high power field satisfies current diagnostic guidelines. However, 
treatment is challenging partly because of the variation in the degree of eosinophil 
infiltration within the esophagus, leading to possible underdiagnosis if the tissue is 
sampled insufficiently [6-8]. Also, patients may require 10-20 procedures to accurately 
determine the triggers to their disease, although such procedures are invasive and 
require anesthesia [9,10].
In EoE, eosinophils release their distinctive, markedly cationic granule proteins 
into the tissues of the affected esophagus. The primary proteins comprising eosinophil
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granules include major basic protein (MBP-1), eosinophil derived neurotoxin (EDN, 
also known as Ribonuclease2), eosinophil peroxidase (EPO), and eosinophil cationic 
protein (ECP, also known as Ribonuclease3), and all of these proteins are 
cytostimulatory and cytotoxic [11-13]. Certain of the eosinophil granule proteins, such 
as MBP-1 and EPO, are among the most basic proteins in the body with isoelectric 
points approaching 12 [14]. Heparin, naturally present in the body, is a highly sulfated, 
polydisperse, linear polysaccharide and the most acidic polysaccharide in the human 
body [14]. Heparin is widely used as a clinical agent and is only biologically active 
when given by intravenous and subcutaneous routes, for prevention and treatment of 
thromboembolic disorders [16-18].
Realizing that these markedly basic proteins deposit in the inflamed esophagus, 
we previously demonstrated that localized inflammation can be detected by incubation 
of 99mTc-heparin [19]. We showed that heparin binds strongly to MBP-1 and found 
significant binding of 99mTc-heparin to eosinophil enriched tissues using single photon 
emission computed tomography (SPECT) [19,20]. These findings identify 99mTc- 
heparin as a potential probe to investigate eosinophil driven inflammation associated 
with EoE and, indeed, of the full gastrointestinal tract.
In the current study, we hypothesized that 99mTc-heparin remains in the GI tract 
and is not appreciably absorbed. This is important because limiting the biodistribution 
of the radionuclide to the GI tract attenuates the radiation risk profile. 99mTc-heparin 
was administered to healthy mice by oral gavage. Qualitative SPECT data and 
quantitative organ biodistributions were obtained to estimate the radiation dosimetry of 
99mTc-heparin. We assayed for radioactivity in each organ of the gut, liver, lung, spleen,
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kidney and other organs within a 30-hour period after the agent was administered. 
These data enable future studies exploring clinically the usefulness of 99mTc-heparin to 
detect EoE associated inflammation.
5.3 Material and Methods
5.3.1 Preparation of 99mTc-heparin. 99mTc-heparin was prepared by diluting 
stannous chloride (5 mg/mL, Sigma 243523) in water under flowing nitrogen. A 0.10 
mL sample was filtered and mixed with 15 mg of preservative free heparin (10,000 
IU/mL, APP Pharmaceuticals, LLC). Approximately 185 MBq (5 mCi) of freshly eluted 
99mTc was added and mixed for 15 minutes at room temperature. Aliquots, 100 ^L, 
containing approximately 18 MBq (0.5 mCi) of 99mTc and 1.5 mg of heparin, were 
removed for oral administration to mice. Quality control was checked by paper 
chromatography (Whatman no. 31) with acetone following manufacturer’s instructions.
5.3.2 Quantitative organ biodistribution. All animal experiments were performed 
in accordance with approved University of Utah Institutional Animal Care and Use 
Committee (IACUC) protocols (Protocol Number: 12-07018). 99mTc-heparin 
(approximately 18 MBq (0.5 mCi)/mouse, 1.5 mg) was administered orally to healthy 
female 13-20 weeks adult mice (C57BL/6, Charles River Laboratories International, 
Inc., average weight = 29.14 ± 1.5 g) by oral gavage under brief restraint using a 
straight 1.5 in., 20-gauge needle with a 1.25 mm ball tip. Three animals per group were 
euthanized with CO2 at 45 minutes, 1.5, 3, 6, 18, and 30 hours. With care to avoid 
cross-contamination, whole organs, blood, and hind leg muscle samples were harvested 
within approximately 20 minutes, weighed, and counted for up to 2 minutes in a Captus
3000 well counter (Bicorn model 2MW2/2-X NaI drilled well crystal detector in a 
Canberra 727 well). The proximal large intestine was considered to include the cecum 
plus 2 cm of the distal bowel, while the remainder was considered distal large intestine. 
Larynx and thyroid were harvested and measured together. Results were expressed as 
the percentage injected dose per gram of harvested organ (%ID/g).
5.3.3 SPECT imaging. To obtain qualitative images of 99mTc activity, mice were 
anesthetized with isoflurane gas (5% induction, 1-2% maintenance, IMWI/VetOne, 
Meridian, ID, Cat# 501017) and positioned prone on the scanner bed 40 minutes prior 
to euthanasia. SPECT/CT images of mice were acquired using an Inveon trimodality 
PET/SPECT/CT scanner (Siemens Preclinical Solutions, Knoxville, TN). A sensor 
(Biovet, France) was used to monitor the respiration rate of mice under anesthesia. CT 
images were first acquired consisting of 220 degrees and 480 projections at each of 2 
bed positions. The exposure time was 135 ms with a detector set to 80 kV peak and 500 
|iA. Data were reconstructed onto a 416*416*752 image matrix using the COBRA 
software package (Exxim Computing Corporation, Pleasanton, CA). The effective CT 
image pixel size was 97 |im. SPECT data were acquired immediately following the CT 
using a 2 mm single pinhole collimator with a detector radius of rotation at 35 mm. 
Images were acquired over 1.5 detector revolutions with 6° between each of 90 
projections. A 90 mm bed travel was used. Each projection was acquired for 12 
seconds, and the data were histogrammed with a 10% window centered at 140 keV. 
Reconstruction was performed using ordered subset expectation maximization 3D 
(OSEM3D) with 8 iterations and 6 subsets. Reconstructed images were analyzed and 
visualized using the Siemens Inveon Research Workplace (IRW) software.
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5.3.4 Dosimetry calculation. The OLINDA/EXM dose estimation software was 
used to determine the effective doses and doses to individual organs via calculations 
and constants defined in the International Commission on Radiological Protection 
(ICRP) Publication 106 [21]. Residence times, t , in the various organs were measured 
using trapezoidal averaging of the mean data for each time interval. The residence time 
of the nuclide is the cumulated activity in the source organ divided by the administered 
activity and is expressed in units of ^ Ci-h/^Ci.
Extrapolation of mouse data to human was accomplished using a well- 
established organ weighting scheme [22],
(o%%0n) = X ( k d T o t a l  B o d y ) m o u se  !  (fe/0"#™ ) (51)\ o r g a n J  h u m a n \ 3  o r g a n /m o#se  \ k3 T o ta lB o d y /h um an
where (%IA/gorgan) is percent injected activity per gram of organ. Each mouse organ 
was weighed and the total body mass of each mouse was used to extrapolate the mouse 
data to human. Average human organ and total body masses were used based on data in 
ICRP 23 and other published sources [23,24].
5.4 Results and Discussion
Here we evaluate the hypothesis that 99mTc-heparin remains in the GI tract using 
quantitative organ biodistributions. To estimate radiation dosimetry, 18 mice received 
orally administered 99mTc-heparin and were sacrificed at six times (3 mice/time). Data 
at each time show recovery of 89-99% of the administered material and 99% of the 
material measured immediately prior to sacrifice.
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Figure 5.1 shows the biodistribution of 99mTc-heparin acquired at time of harvest 
as measured by well counting. Forty-five minutes after oral administration, the stomach 
and small intestines account for the majority of the 99mTc-heparin. The proximal large 
intestine shows the highest uptake 1.5 hours after oral administration. The majority of 
activity after 6 hours of incubation of 99mTc-heparin appears in the distal large intestine. 
Little uptake appears in the esophagus, lung, and thyroid. The very modest uptake in the 
lung and esophagus may be due to esophageal reflux associated with oral gavage. All 
other organs show negligible uptake at all time points, indicating that 99mTc-heparin is 
not a significant contributor to organ and effective dose outside the GI tract. Indeed, 
over 98% of the accumulated activity resides in the GI tract alone.
To visually track the localization of radiolabeled dose in mice, SPECT/CT 
images were taken 40 minutes prior to euthanasia. Figure 5.2 shows the SPECT/CT 
images acquired at 3, 6, 18, and 30 hours after oral administration of 99mTc-heparin. At 
3 and 6 hours post administration, the majority of activity remains mostly in the GI 
tract, particularly in the stomach and intestines. Negligible localization appears in the 
liver, kidney, and lungs, indicating that 99mTc-heparin neither absorbs significantly 
through the GI tract nor circulates in the blood stream. The radioactivity is negligible in 
all of the organs at longer time points (18, 30 hours), confirming that 99mTc-heparin is 
not absorbed.
Figure 5.3 shows the average net activity (^Ci) at each time interval represented 
as the number of disintegrations per unit of administered activity (^Ci-h/^Ci) in each 
source organ. The stomach and small intestines show the highest initial uptakes 
followed by gradual decreases. Uptake by the proximal and distal intestine gradually
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increases over 3 and 6 hours, respectively, and then decreases thereafter. Little 
radioactivity is observed in the esophagus, lung, and thyroid, and negligible activity 
appears elsewhere.
Table 5.1 shows estimated residence times in humans from orally administered 
99mTc-heparin. Equation 5.1 provides the scaling necessary to convert the mouse 
measured average accumulated activities into human equivalents by source organ. The 
table lists these results in descending order based on the dose to the organ.
OLINDA/EXM dose estimation software estimates the total effective dose for 
humans. The results for a standard adult are shown in Table 5.2. Approximately 74% of 
the contribution to the effective dose derives from the organs in the GI tract. For 
example, the doses to the ovaries and bone marrow result from the accumulated activity 
of other organs (i.e., irradiation from accumulated activity in surrounding organs), 
because accumulated activity in these organs was not specifically measured.
Given that greater than 98% of the accumulated activity appears in the GI tract 
and the contribution to the effective dose from these organs accounts for approximately 
75% of the dose, additional resolution of the observed uncertainties is unlikely to result 
in more than a 25% change in the estimated dose to human subjects. Potential 
improvements to the experimental process include improving the collection fraction and 
better accounting for dose in organs receiving less than 2% of the total accumulated 
activity, but such improvements will likely have only a small to negligible effect on the 




These proof-of-principle experiments clearly show that 99mTc-heparin remains in 
GI tract. Indeed, 99mTc-heparin was not absorbed significantly into other bodily tissues. 
Furthermore, because heparin and short-lived 99mTc have long been used in clinical 
medicine, we believe that the conjugates will be well tolerated in our patients. These 
findings are important because they initiate a new avenue for clinical detection of 
eosinophil-associated inflammation.
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Figure 5.1. Biodistribution of 99mTc-heparin in collected organs as measured using a 
well counter at different times. Arithmetic means and standard deviations of %ID/g are 
corrected for physical decay of the isotope. In=Intestine, Lg=Large, Prox=Proximal, 
Dist=Distal.
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Figure 5.2. SPECT/CT images of " mTc-heparin orally administered to mice at 3, 6, 18, 
and 30 hours. St=stomach, In=Intestines. SPECT/CT intensity were optimized 
separately in each image and set higher at later time points to reveal locations of 
radioactivity. The optimization is based off of revealing locations of radioactivity. We 
started by applying based off of the inflection point of the histogram being set to max, 
then adjusting mildly further reducing the max given the lack of signal. The bed, 
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Figure 5.3. Average (and 95% confidence interval) net activity (^Ci) of GI tract organs 
(a) esophagus, (b) stomach, (c) small intestine, (d) proximal large intestine, and (e) 
distal large intestine at each time interval (0.75, 1.5, 3, 6, 18, and 30 hours) expressed as 
residence time, t  (^Ci-h/^Ci).
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Table 5.1. Estimated residence times in humans.
Organ A (|iCi- h/^Ci)
Fraction of 
Total
Dist. Lg. In. 0.4355 0.2916
Small Int. 0.4226 0.2829
Prox. Lg. In. 0.3602 0.2411
Stomach 0.2541 0.1701
Lung 0.02012 0.01347
Urine 3.830 10-4 2.56410-4
Liver 2.708 10-4 1.813.10-4
Esophagus 2.359 10-4 1.579.10-4
Larynx/Thyroid 1.38110-4 9.248 10-5
Bladder 9.002 10-5 6.02610-5
Kidney 7.91810-5 5.30010-5
Heart 4.28110-5 2.86610-5
Trachea 3.724 10-5 2.493 10-5
Pancreas 2.300 10-5 1.540.10-5
Spleen 1.452 10-5 9.71910-6
Testicles 1.206 10-6 8.07210-7
Thymus 6.022 10-7 4.03210-7
Gall Bladder 5.582 10-7 3.73710-7
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Table 5.2. OLINDA estimates for a standard adult human using estimated residence 
times.
mGy/MBq Fraction of Total Dose
Lower Large Intestine 
Wall 2.4610"3 0.512
Stomach Wall 1.0410-3 0.217
Ovaries 8.8710-4 0.0185
Red Marrow 1.0210-4 0.0212
Upper Large 6.8310"5 0.0142IntestineWall
Urinary Bladder Wall 6.6410"5 0.0138
Lungs 4.9210"5 0.0102
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CHAPTER 6
99MTC-HEPARIN: KINETICS OF BINDING 
6.1 Abstract
Due to the ability of heparin binding to eosinophilic granule proteins, such as 
major basic protein (MBP-1), 99mTc-heparin can be used as an imaging contrast agent to 
detect inflammation and eosinophil granule proteins deposition in eosinophilic 
esophagitis (EoE). Here we evaluate the kinetics of binding of 99mTc-heparin to non­
human primate tissue (ex vivo monkey esophagus) and model the amount of binding to 
the esophageal wall versus drinking times and flow rates. This information will inform 
99mTc-heparin administration protocols, optimize the imaging intensity corresponding to 
the bound material to the esophageal wall, and lead to better detection of eosinophil 
granule proteins density in EoE patients.
6.2 Experimental Values for Rate Constants
To model the swallowing of 99mTc-heparin to the esophageal wall, we need to 
first experimentally determine the “on” and “off’ rate constants of the radiolabeled 
conjugate to the esophageal wall.
6.2.1 Experimentally determined “on” rate constant. To calculate the on-rate 
constant, kon, the radiolabeled heparin was incubated with biopsy-sized monkey
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esophageal tissue treated overnight with MBP-1. Intact frozen monkey esophagi were 
provided from CA National Primate Research Center, UC Davis. The monkey esophagi 
were thawed and washed several times with Ringer’s solution (Sigma-Aldrich K4002) 
and the fats were removed carefully prior to the experiment. The monkey esophagus 
was opened up, and the epithelium layer (soft tissue in white color) was carefully 
separated from the deeper tissue (muscle layer, dark red color tissue) using small 
scissors and forceps. The epithelium layer was then cut in approximately equal size 
biopsies (approximately 2 mm by 2 mm). The tissue samples were incubated overnight 
with approximately 0.2 mg/mL MBP-1 solution (made freshly from stock solution in 
1X PBS before use). The next day, the samples were taken to Intermountain 
Radiopharmacy. Freshly prepared 99mTc-heparin (approximately 15 mg heparin, 10 mCi 
99mTc, see Material and Methods section of Chapter 4 for details) was used. The tissue 
radioactivity was measured using a dose calibrator (Capintec model CRC-15R) after 
incubation with 99mTc-heparin for 10, 30, 60, and 90 minutes. For each time point, two 
experiments were conducted, and the average activity after two quick washes in 1X 
PBS was reported. The result in Figure 6.1a shows that the reaction follows a first order 
reaction dA/dt=konA, or Ln(A/Ao)=kon(t-to). This can be rearranged into the equation of a 
line on a log-linear plot (Ln(A)=kont+[Ln(Ao)-konto,]). The slope of the semi-log plot of 
activity versus time gives us the value for kon (see Figure 6.1b). Rate constant kon in our 
experiments is 0.0149 1/min (range: 0.0052 to 0.035 1/min). This means that the 
characteristic on time (=1/kon) is 67.1 min (range: 28 to 192 min).
6.2.2 Experimentally determined “off’ rate constant. The radiolabeled heparin 
was incubated with biopsy-sized monkey esophageal tissue treated overnight with
MBP-1 (solution concentration of approximately 0.2 mg/mL, details mentioned above). 
The following day, at the Intermountain Radiopharmacy (IRP) at University of Utah,
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samples. The tissue was then washed every 2 minutes for a period 64 minutes in 1X 
PBS and the radioactivity was measured using a dose calibrator (Capintec model CRC- 
15R). The experiment was done in triplicate and the average radioactivity over time was 
reported. As shown in Figure 6.2a, the reaction follows a first order reaction. The slope 
of the semi-log plot of activity versus time gives us the value for off-rate constant, koff, 
(see Figure 6.2b). The experimental value for off-rate constant koff is 0.0146 1/min 
(range: 0.004 to 0.03 1/min).
The binding ratio (Kratio) is defined as,
99mTc-heparin was incubated for 20 minutes with the MBP-1 treated monkey esophagus
(6.1)
which is approximately 1, with the range of 0.1 (Kratio !\ c o (V max\) to 5.8 (Kratio ).
6.3 Modeling the Swallowing of 99mTc-heparin
The swallowing process can be modeled by
dCf
= DV2Cf — konCf + k0f f  Cb (6.2)
(6.3)
where
Cf = Free radiolabeled conjugate at the esophageal wall (decay not included),
Cb = Bound radiolabeled conjugate at the esophageal wall (decay not included), and 
D = Diffusion coefficient.
The first term on the left side of Equation 6.2 is the accumulation of free 
(unbound) radiolabeled conjugate. The terms on the right side of Equation 6.2 are the 
diffusion term and source terms (consumption and the production term), respectively. In 
this study, the bound material correlates with the amount of MBP-1 deposition in 
diseased esophagi. For Equation 6.3, the left-hand side is the accumulation of bound 
material, which is equal to the production and the consumption term, respectively, on 
the right-hand side of the equation. Adding Equations 6.2 and 6.3 together, the total rate 
of change of bound and free material is equal to diffusion of free (unbound) material to 
the esophageal wall.
To solve the swallowing process numerically, the equations are scaled with 
scaled variables given in Equation 6.4. The reaction time scale, i.e., 1/kon, is used for 
characteristic time scale.
Cf = Cb = ^ , i  — £  — kont, x = R (6.4)




where, R is the thickness of mucosa layer (3 mm), approximated from the 
esophagectomy sample (details given in Chapter 2), Q is the volumetric flow rate (the 
rate of the material flow through the esophagus), and td is the drinking time.
The Damkohler number (Da) is the ratio of diffusion time scale to reaction time 
scale, which is defined as
„  D if fu s io n  tim e scale  , R2 .Da = -----------------------= knri —. (6.6)
Reaction  tim e scale D
The diffusion coefficient (D) is calculated by the Stoke-Einstein equation for 
water properties at 20°C (room temperature at which the experimental values of rate 
constant were calculated). This assumption is more accurate for diseased esophagus, 
where there is an increase in extracellular spaces and the junctions between cells are not 
as tight as in normal tissue (see the increase in intercellular spaces in electron 
microscopy figures in Chapter 3).
By substituting Equation 6.4 and using Damkohler number, the scaled form of 
Equations 6.2 and 6.3 become
V2!  -  Cf + Kratio !  (6.7)
dCf
— ! ratio ! b (68)
Since, the radioactivity of materials decay over time, the activity of bound and 
free radiolabeled conjugate in Equations 6.7 and 6.8 will follow a decay function
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-Ln(2)^ —£”(2)^
^f decayed. = !! e * ^ ^ d e c a y e d  =  ! ! ! * , (6 9 )
where, tm= Technetium-99m half life ~ 6 hours.
Therefore the new-scaled equations, which include the radioactivity decay over 
time are given in Equation 6.10 and 6.11. Note that from hereafter the scaled bound and 
free material includes the decay factor and the subscript “decayed” is eliminated for 
simplicity.
§  = - k  v2! - ( 1 + y )  <610)
The scaled initial value and boundary conditions (B.C) are:
cb se =  0 @ x = 1
t
= 1 0 < — < 1
t
= 0 — >
!d
1
cb dna ! f = 0 @ t =: 0
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The total bound radiolabeled conjugate (Cbtotal) and the total free radiolabeled 
conjugate (Cfotal) were calculated as a function of depth in the tissue of the esophageal 
wall by solving the equations above.
to ta l
Jo* ! f  dx (6.12)
Four integral domains were selected to calculate the total bound and free 
radiolabeled conjugate: (1) 0 to 0.1 mm (the lumen surface and the depth of 10 cells 
with the assumption of each cell being ~ 0.01 mm, respectively); (2) 0 to 0.2 mm (depth 
of ~ 20 cells); (3) 0 to 0.3 mm (depth of ~ 30 cells); and (4) the total esophageal depth 
of ~ 3 mm. The ratio of Cbtotal to Cfotal was also calculated. In order to distinguish the 
bounded conjugate from free (unbound conjugate), the ratio of Cbtotal to Cfotal should 
remain higher than 3 (>75% of the intensity is from binding of radiolabeled material to 
eosinophilic granule proteins). The equations were solved for clinical relevant drinking 
time of 5, 15, and 30 minutes with a flow rate of 1 mL per minute (low enough to avoid 
bolus flow which drives material past the esophagus without significant binding time), 
and the time for imaging the esophagus was estimated based on Cbtotal/Cfotal>3 (see 
Figures 6.3-6.8). Results are reported without scaling. Note that the _y-axes in Figure 
6.3-6.9 are converted to 1/mL such that one can multiply the initial activity to estimate 
the amount of bound/free material in activity/mL units (a standard protocol in medicinal 
physics).
The results from 5, 15, and 30 minutes drinking time with flow rate of 1 
millimeter per minute suggest that the imaging window starts after 10 minutes to ensure
the ratio of total binding to free conjugate be higher than 3, for the first 0.1 mm in depth 
of esophageal tissue.
The results also depend on the variability in the kinetic rate constants. To 
evaluate the effect of kinetic rate constant, the equations were numerically solved at the 
lowest and highest value of Kratio (0.1 and 5.8, respectively) and the Cbtotal , Cfotal, and 
Cbtotal/Cfotal were estimated at constant drinking time of 15 minutes (clinically relevant 
value) and flow rate of 1 mL/min (see Figures 6.9-6.12). The results clearly show that 
the amount of bound material increases significantly, by a factor of at least three, at low 
Kratio (=0.1, see Figure 6.9). The ratio of c btotal/Cfotal increases remarkably (>20 after 20 
minutes, and increases to >100 in an hour), which promises good imaging quality. 
Conversely, at maximum Kratio (=5.8), the c btotal/C^otal never reaches the value of 3, 
because the amount of bound material decreases dramatically by approximately 10 fold 
(see Figure 6.5 and 6.11). These findings are very helpful to estimate the esophagus- 
imaging window in EoE patients.
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Figure 6.1. Biopsy-sized monkey esophageal tissue treated with MBP-1, incubated with 
radiolabeled heparin at different times. Rate constant kon in our experiments is 0.0149 
1/min (range: 0.0052 to 0.035 1/min). This means that the characteristic on time (=1/kon) 
is 67.1 min.
94
Figure 6.2. Biopsy-sized monkey esophageal tissue treated with MBP-1, incubated with 
radiolabeled heparin at different times. Rate constant koff in our experiments is 0.0146 
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Figure 6.3. Total bound radiolabeled and total free radiolabeled material as a function of 
time at different integral domain (0.1 mm=10 cell thickness, 0.2 mm=20 cell thickness, 
0.3 mm=300 cell thickness, and full 3 mm esophageal thickness. The simulation is 
based on Krafio=1, drinking time=5 min, and volumetric flow of 1 mL/min.
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Figure 6.4. Ratio of bound radiolabeled to free radiolabeled material as a function of 
time at different integral domain (0.1 mm=10 cell thickness, 0.2 mm=20 cell thickness, 
0.3 mm=300 cell thickness, and full 3 mm esophageal thickness. The simulation is 
based on Kratio=1, drinking time=5 min, and volumetric flow of 1 mL/min. The 
horizontal dash line indicates the lower limit of detection (ratio>3).
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Figure 6.5. Total bound radiolabeled and total free radiolabeled material as a function of 
time at different integral domain (0.1 mm=10 cell thickness, 0.2 mm=20 cell thickness, 
0.3 mm=300 cell thickness, and full 3 mm esophageal thickness. The simulation is 




Figure 6.6. Ratio of bound radiolabeled to free radiolabeled material as a function of 
time at different integral domain (0.1 mm=10 cell thickness, 0.2 mm=20 cell thickness, 
0.3 mm=300 cell thickness, and full 3 mm esophageal thickness. The simulation is 
based on Kratio=1, drinking time=15 min, and volumetric flow of 1 mL/min. The 
horizontal dash line indicates the lower limit of detection (ratio>3).
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Figure 6.7. Total bound radiolabeled and total free radiolabeled material as a function of 
time at different integral domain (0.1 mm=10 cell thickness, 0.2 mm=20 cell thickness, 
0.3 mm=300 cell thickness, and full 3 mm esophageal thickness. The simulation is 
based on Krat;o=1, drinking time=30 min, and volumetric flow of 1 mL/min.
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Figure 6.8. Ratio of bound radiolabeled to free radiolabeled material as a function of 
time at different integral domain (0.1 mm=10 cell thickness, 0.2 mm=20 cell thickness, 
0.3 mm=300 cell thickness, and full 3 mm esophageal thickness. The simulation is 
based on Kratio=1, drinking time=30 min, and volumetric flow of 1 mL/min. The 
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Figure 6.9. Total bound radiolabeled and total free radiolabeled material as a function of 
time at different integral domain (0.1 mm=10 cell thickness, 0.2 mm=20 cell thickness, 
0.3 mm=300 cell thickness, and full 3 mm esophageal thickness. The simulation is 
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Figure 6.10. Ratio of bound radiolabeled to free radiolabeled material as a function of 
time at different integral domain (0.1 mm=10 cell thickness, 0.2 mm=20 cell thickness, 
0.3 mm=300 cell thickness, and full 3 mm esophageal thickness. The simulation is 
based on Kratio=Kmin=0.1, drinking time=15 min, and volumetric flow of 1 mL/min. The 
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Figure 6.11. Total bound radiolabeled and total free radiolabeled material as a function 
of time at different integral domain (0.1 mm=10 cell thickness, 0.2 mm=20 cell 
thickness, 0.3 mm=300 cell thickness, and full 3 mm esophageal thickness. The 
simulation is based on Kratio=Kmax=5.8, drinking time=15 min, and volumetric flow of 1 
mL/min.
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Figure 6.12. Ratio of bound radiolabeled to free radiolabeled material as a function of 
time at different integral domain (0.1 mm=10 cell thickness, 0.2 mm=20 cell thickness, 
0.3 mm=300 cell thickness, and full 3 mm esophageal thickness. The simulation is 
based on Kratio=Kmax=58, drinking time=15 min, and volumetric flow of 1 mL/min.
CHAPTER 7
CONCLUSIONS
The general purpose of this project is to develop a minimally invasive technique 
to detect eosinophil-associated inflammation in eosinophilic esophagitis (EoE). Current 
diagnosis is to monitor the involvement through biopsy samples, which is invasive and 
may not fully represent the disease state. We hypothesized that 99mTc-heparin can be 
used as a radiolabeled agent to detect the eosinophil’s proteins degranulation in the 
diseased esophagus. Our long-term plan is to have patients swallow the reagent and 
image its binding by single-photon emission computed tomography (SPECT) imaging.
To achieve our goal, we first studied the disease patchiness by mapping the 
eosinophils density of the esophagectomy sample from a known EoE patient and found 
that misdiagnosis may be possible by esophagogastroduodenoscopy (EGD), if not 
sampling adequately. Second, we studied degranulation patterns in EoE from 9 
randomly selected patients and found that more than 80% of the eosinophils are 
undergoing cytolysis by releasing their markedly basic granule protein in the tissue. 
With the realization that these proteins are deposited in the inflamed esophagus, we 
further hypothesized that the eosinophils associated inflammation by detecting the 
granule proteins degranulation such as major basic protein (MBP-1), could be detected 
and localized by swallowing radiolabeled heparin. We radiolabeled heparin with
technetium-99m (99mTc-heparin) and tested the binding using both paper and column 
chromatography. The binding efficiency was more than 98% and stable for more than 
10 hours (more details in Chapter 4), indicating that technetium binds strongly to 
heparin. We then tested the ability of 99mTc-heparin binding to cationic eosinophil 
granule proteins, and we found that 99mTc-heparin would bind to tissues coated with 
these eosinophil granule proteins. We also have been able to demonstrate that the 
radiolabeled heparin is able to bind in vitro to biopsies of the esophagus from patients 
with EoE using SPECT imaging. The animal study was done in healthy mice to 
evaluate the biodistribution of 99mTc-heparin administered orally. The results showed 
that the majority of the conjugate is not absorbed through the gastrointestinal tract. The 
human dosimetry was done based on the mice data and the radiation dose to each organ 
was estimated.
This work lays an important foundation for clinical trials of this reagent. 
Presently, our proposal to perform the first trials of this reagent in human subjects is 
under review by the Radioactive Drug Research Committee (RDRC) at University of 
Utah. We propose to do basic science research on humans to determine the distribution 
of the 99mTc-heparin and whether radiolabeled heparin localizes specifically to the 
esophagus of patients with eosinophilic esophagitis. We desire to test whether 
radiolabeled heparin will bind to the eosinophil’s granule protein in eosinophilic 
esophagitis patients, because an animal model of eosinophilic esophagitis, which shows 
the striking deposition of eosinophil granule proteins remains unavailable. Furthermore, 
because heparin is a physiological substance that has long been used in clinical 
medicine, we believe that it will be well tolerated in our patients.
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We believe that with radioimaging we can more fully appreciate the eosinophil 
involvement throughout the entire length of the esophagus by having the patients 
swallow a radiolabeled agent specific to eosinophil granule proteins. If successful, this 
will open a new avenue to clinically monitor the disease state and to better understand 
the disease pathogenesis.
APPENDIX A
ADDITIONAL INFORMATION: ESOPHAGECTOMY SECTIONS
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Figure A.1. Digital image of representative H&E stained esophageal section and 
eosinophil density (in eos/hpf and eos/mm2) as a function of lumenal perimeter position 
in terms of microscopy sites for section 3B. The start point is shown by “x” marker 
following the direction with an “arrow” on the digital pictures.
Figure A.2. Digital image of representative H&E stained esophageal section and 
eosinophil density (in eos/hpf and eos/mm2) as a function of lumenal perimeter position 
in terms of microscopy sites for section 3C. The start point is shown by “x” marker 
following the direction with an “arrow” on the digital pictures.
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Figure A.3. Digital image of representative H&E stained esophageal section and 
eosinophil density (in eos/hpf and eos/mm2) as a function of lumenal perimeter position 
in terms of microscopy sites for section 3D. The start point is shown by “x” marker 
following the direction with an “arrow” on the digital pictures.
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Circumferential Site Number
Figure A.4. Digital image of representative H&E stained esophageal section and 
eosinophil density (in eos/hpf and eos/mm2) as a function of lumenal perimeter position 
in terms of microscopy sites for section 3E. The start point is shown by “x” marker 





















Figure A.5. Digital image of representative H&E stained esophageal section and 
eosinophil density (in eos/hpf and eos/mm2) as a function of lumenal perimeter position 
in terms of microscopy sites for section 2Y. The start point is shown by “x” marker 
following the direction with an “arrow” on the digital pictures.
Figure A.6. Digital image of representative H&E stained esophageal section and 
eosinophil density (in eos/hpf and eos/mm ) as a function of lumenal perimeter position 
in terms of microscopy sites for section 2X. The start point is shown by “x” marker 
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Figure A.7. Digital image of representative H&E stained esophageal section and 
eosinophil density (in eos/hpf and eos/mm2) as a function of lumenal perimeter position 
in terms of microscopy sites for section 2W. The start point is shown by “x” marker 


















Figure A.8. Digital image of representative H&E stained esophageal section and 
eosinophil density (in eos/hpf and eos/mm2) as a function of lumenal perimeter position 
in terms of microscopy sites for section 2U. The start point is shown by “x” marker 
following the direction with an “arrow” on the digital pictures.
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Figure A.9. Digital image of representative H&E stained esophageal section and 
eosinophil density (in eos/hpf and eos/mm2) as a function of lumenal perimeter position 
in terms of microscopy sites for section 2T. The digital picture of slide 2T had two 
marking sites (not on the epithelium layer, i.e., the mapping region) upon receipt from 
the Department of Pathology. The start point is shown by “x” marker following the 
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Figure A.10. Digital image of a longitudinal section representative H&E stained 
esophageal section and eosinophil density (in eos/hpf and eos/mm2) as a function of 
lumenal perimeter position in terms of microscopy sites. The start point is shown by 
marker following the direction with an “arrow” on the digital pictures.
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APPENDIX B
ADDITIONAL DESCRIPTION OF THE SIMULATION PROTOCOL
A Monte Carlo simulation was coded in Visual Basic for Applications (VBA) in 
MS Excel 2003. The 2003 version was selected because it executes the code 20-30% 
faster than more recent versions. A key attribute of these simulations is that they 
directly use the recorded eosinophil densities collected above. The code randomly 
selects a row and column representing the eosinophil density from a worksheet in which 
all of the data are summarized. Each column represents a circumferential or longitudinal 
section of the esophagus. Each row represents a site for counting. If the density exceeds 
15 eos/hpf, then the sites are designated as diseased. Four immediately adjacent sites 
constitute a biopsy because each biopsy typically spans approximately 2 mm and each 
site represents a 0.54 mm diameter field of view. To be representative of the clinical 
practice of reporting only peak eosinophil densities, if only one of the four sites within a 
biopsy exceeds 15 eos/hpf, then the entire biopsy is designated as diseased. The process 
is repeated two to forty times to represent multiple biopsy collection per endoscopy. 
The result of each endoscopy (1 for diseased and 0 for normal) is stored in an array. Ten 
thousand biopsies are collected for each condition. The average, ^, and standard 
deviation, o  are calculated from the 10,000 entries in the array.
The simulation analyzed three sample patterns at three eosinophil site densities. 
The average eosinophil site density (30.2%) was simulated by allowing column 
selection from all available columns. The low eosinophil site density (5.7%) was 
simulated by allowing column selection from the three columns with the fewest number 
of sites with eosinophil densities exceeding 15 eos/hpf. The high eosinophil site density 
(79.3%) was simulated by allowing column selection from the three columns with the 
most number of sites with eosinophil densities exceeding 15 eos/hpf. Three sampling
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patterns were also evaluated. Purely random sampling was imitated by using the Rnd 
functionality to randomly select both the allowed column and row for each biopsy. 
Random sampling from within a section was simulated by first designating a column 
corresponding to a section and then repeatedly and randomly selecting rows using the 
Rnd functionality in that column. Random sampling within a sector of a section was 
accomplished by first selecting one column for all biopsies in an endoscopy. The 
number of available sites (rows) was divided by the number of sites to determine which 
sites correspond to which sector. Random sampling within that narrow sector was then 
accomplished using the Rnd functionality. Since all sectors are of equal length a sector 
represents a fraction of the perimeter, which may or may not correspond with sectors 
defined by angle because the eosophageal lumen is not strictly circular. If four 
consecutive sites exceed the number of rows, sampling within a biopsy restarts at the 
top row, even for sector sampling. Only nonempty cells were employed.
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APPENDIX C
ADDITIONAL INFORMATION: ELECTRON 
MICROSCOPY GRADINGS
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Table C.1. The average (Avg) and standard deviation (Std) of 1672 electron 
photomicrographs (9 EoE patients, 900 eosinophils) graded by three individuals based 
on membrane integrity, evidence of cytoplasmic vesiculation including sombrero 
vesicles, granule morphology, and extracellular granule location. Cytoplasmic 
membrane integrity was classified as intact (no membrane loss), mainly intact (<20% 
membrane loss), partially disrupted (>20% membrane loss), or fully disrupted (no 









Avg ± Std 1185± 68 641 ± 55 483 ± 66 11 ± 2












Avg ± Std 116 ± 34 124 ± 21 175 ± 42 334 ± 26












Avg ± Std 18 ± 7 4 ± 2 6 ± 3 15 ± 3













Avg ± Std 16 ± 20 18 ± 22 6 ± 7 36 ± 47















Avg ± Std 13 ± 4 6 ± 4 1 ± 0 2 ± 2
APPENDIX D
CALIBRATION CURVE: ACTIVITY 
VERSUS SPECT INTENSITY
In all experiments, the activity of radiolabeled biopsy tissues was measured 
using a dose calibrator (Capintec model CRC-15R). Two-dimensional planar static 
images of the radiolabeled biopsies were obtained using the Ecam SPECT instrument 
(Siemens). The calibration curve between the activity measurement and the SPECT 
intensity was checked at different days. Some variation from the linear curve of SPECT 
count versus activity can be because of the radioactivity decay, error in the activity 
measurement and SPECT count, time variation between each measurement, and the 
transportation of samples from Radiopharmacy to Nuclear Medicine.
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Figure D1. Correlation curve of activity measurement on ex vivo monkey esophageal 





In addition to heparin, alternative radiolabeled chelating agents such as anti- 
MBP1 antibodies, polyanions (poly-glutamic acid and poly aspartic asid), SAGE 
polymers (semisynthetic glycosaminoglycan ethers, provided generously by Dr. Glenn 
Prestwich at the University of Utah), and enoxaparin (NDC 0075-0623) were also used to 
evaluate the hypothesis. In this appendix, the radiolabeling procedure and the limitations 
are briefly discussed.
Antibody Radiolabeling 
A murine monoclonal anti-MBP (J13-6B6) supernatant synthesized previously by 
Gleich’s lab was purified using MabTrap Kits (Sigma, 54842). The amount of antibody 
purified in each cycle was approximately 12 mg in 6 mL elution buffer. The purified anti- 
MBP antibody was then mixed with NHS-MAG3 (N-hydroxysuccinimidyl S- 
acetylmercaptoacetyltriglycinate) to the ratio of 1:15. After vortexing and incubating the 
mixture for 2 hours at room temperature, the solution was run through a G25 Sephadex 
column (GE healthcare, 11-0003-29) to separate the conjugated antibody-MAG3 
complex from the free NHS-MAG3. The step-by-step protocol of chelating has been 
described in full detail by Wang, et al., and the authors generously provided the chelator 
NHS-MAG3 [12]. The peak fractions were combined and stored at 4oC for radiolabeling 
experiment.
To label the antibody with Tc-99m, 600 |ig of antiMBP antibody-MAG3 was 
mixed with 1 mL Tc-99m (200 mCi), 0.6 mL tartrate buffer, 0.2 mL fresh stannous 
chloride solution, and 1 mL 0.25 M ammonium acetate. The mixture was then applied on 
a G-25 desalting column (GE healthcare, 17-1408-1), and the radioactivity of the
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fractions was measured using the calibrator available at the radiopharmacy facility. The 
maximum (highest) peak was then used for labeling monkey esophagi samples.
The binding affinity of radiolabeled antibody was also checked with a desalting 
column (see Figure E.1). With antibodies, a small second peak appeared in the activity 
measurements of eluted fractions, which means that the antibody was completely 
saturated with Tc-99m (peak at fraction 3) and the free Tc-99m eluted from the column at 
the second peak (fraction 11). As shown in Figure E.1, the peak in absorbance 
corresponds to the peak in radioactivity.
Plastic tubes (height: 4.8 cm, diameter: 0.4 cm, volume: 1.2 mL) were filled up 
with approximately 0.2 mg/mL MBP-1 solution (freshly prepared in 1X PBS) and was 
enclosed with parafilm and incubated overnight in a fridge at 4°C. A control sample was 
filled up with 1X PBS only. The following day, the samples were washed and incubated 
with peak fractions from the G-25 column (approximately 20 mCi 99mTc-antiMBP) for 3 
hours. The samples were taken to Nuclear Medicine at University of Utah hospital and 
SPECT images were acquired. As shown in Figure E.2, the intensity of the treated sample 
is significantly higher than the control sample (not treated with MBP-1).
Although the binding of the 99mTc-antiMBP antibodies to the tissue is promising 
(see Figure E.2), there are several disadvantages of using the anti-MBP antibodies as the 
targeting candidate. First, the source of anti-MBP antibodies is very limited and 
expensive to reproduce. Second, numerous steps are needed to synthesize and purify the 
antibody and to use MAG3 as a chelating agent, leading to more complicated procedures 
than radiolabeling heparin. Third, the binding efficiency of the antibody is lower than of 
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Figure E.1. Sample measurements. (a) Activity of 99mTc-antiMBP of fractions eluted 
from desalting column. (b) Absorbance at 280 nm for decayed 99mTc-antiMBP as a 





Figure E.2. SPECT image of plastic tube coated with and without MBP-1 (control), both 
incubated with 99mTc-antiMBP for an hour.
Polyanion Radiolabeling 
To label the polyanions, the same procedure with heparin conjugation was used 
except that the heparin was substituted with polyanions (poly-glutamic acid and poly- 
aspartic acid). The repeatability of the labeling experiments was not achieved, because 
after mixing for 15 to 30 minutes with fresh (unfiltered) tin solution and adding the 99mTc, 
the solution precipitated and was no longer clear.
SAGE Polymer Radiolabeling 
With SAGE polymers (semisynthetic glycosaminoglycan ethers, provided 
generously by Dr. Genn Prestwich at University of Utah), the solution started to 
precipitate after radiolabeling. Also, due to the limited access of SAGE polymers, and the 
availability of pharmaceutical grade heparin, further investigation on this particular 
polymer was not pursued.
Enoxaparin Radiolabeling 
Enoxaparin is a low molecular weight heparin (5 kDa versus 15 -  30 kDa for the 
heparin explored elsewhere herein). Successful radiolabeling of enoxaparin was achieved 
and the labeling efficiency was the same as that of the higher molecular weight heparin 
indicated in Chapter 4. However, the binding affinity of enoxaparin to the eosinophil’s 
granule proteins was lower than that of the higher molecular weight heparin
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